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INTRODUCTION 
Siddha system is the most ancient traditional medicine it is taught that the 
siddhars laid the foundation for this system medication which is enriched with flora, 
fauna, mineral resources. Their contributions are well known in the field of Medicine, 
alchemy, meditation & yogic practices, knowledge & almighty. 
          Siddhars is “One who is accompalished” it refers to perfected masters who have 
achieved a high degree of physical as well as spiritual perfection or enlightenment.. 
They used such powers to control, time, space, body transformation, achieving 
immortality. And they practiced intense yogic practices including years of periodic 
fasting and meditation and were believed to have achieved supernatural power and 
gained the supreme wisdom &over all immortality. 
The siddhars were possessing tremendous powers in themselves and could 
sustain their bodies for ages. They held that the body is the only instrument  with which 
one could attain success in spiritual evolution and thereby get rid of diseases, decay, 
death. 
Siddhars have explained more about the medicinal characters of all forms of 
herbo-mineral formulations and their purification techniques. Their knowledge of 
synergistic& antagonistic action of metals& minerals and herbal juice made them to 
formulate and detoxifying and their own acids and alkalines make the material into fine 
molecules which are easily absorbed in the body. 
Siddhars had the knowledge of converting inorganic substances into nano and 
ionic form which is easily absorbed by the human cells. And it is easily penetrating and 
targeting the cells. The siddhars were efficient in distillation, calcinations, oxidations 
of metal by those process fit for human consumption those medium play their effective 
role in the treatment of incurable chronic disease. 
Siddhar AGASTHIYAR, the most distinguished person in realm of tamil siddha 
medicine system is one among the 18siddhars.They belong to the class of 18 supernals 
or demigods, inhabiting the middle air and embracing several subdivisions. They also 
make not only of certain special medicinal drugs but also metallic preparations such as 
Mercury, sulphur, arsenic, gold etc… 
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           Rasa means elixir of life and it is extensively used in the preparation of SIDDHA 
medicine after purification it is converted into healing nectar not only cures 
innumerable chronic diseases.  
Also used in the alchemical rejuvenation medicine, anti oxidants, corporeal 
transmutation. Specially in siddha medicines mercury is used in the form of higher 
order medicines like parpam,chenduram,pathangam ,mezhugu,etc… are classified 
under “ULL MARUNDHUGAL 32”  it is highly potent,longer shelf life, vast 
utility,fast action ,only smaller dose is enough,promotes longevity. 
Rheumatoid arthritis is a generalised chronic multisystem disease affecting 
the connective tissues of the whole body with focalized involvement of the 
musculoskeletol system . 
            Though the most prominent manifestation of RA is inflammatory arthritis of the 
peripheral joints  usually with symmetrical distribution followed by pain 
swelling,stiffness of the joints especially involving joints of hands,wrist,and feet and 
later on spread to the proximal joints such as the knee, hips, elbow, shoulder. 
        It is considered to be an auto immune response to an unknown antigen and the 
antibody formed is the rheumatoid factor which is identified as immunoglobulinM 
autoantibody  is directed against the Fc portion of IgG antibodies. 
          RA is a common disease having peak incidence in 3rd and 4th decades of life with 
3-5 times higher prepondarence in females .The Onset of disease is insidious, beginning 
with prodrome of fatigue, weakness, vague arthralgias and more frequent between 
25and 40 years of age, but any age can be affected. 
 The individuals with histocompatibility such as high association with HLA-DR4 , 
HLA_DR1 and familial aggregation. 5% of the women and 2% of the men over the age 
of 55 years are affected. 
       In modern aspects it is treated with NSAIDs, DMARDs drugs and the surgical 
procedures are synovectomy in early stage, in later arthroplasty, arthrodesis. 
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         To evaluate the siddha herbo-mineral formulations of RASA CHENDURAM 
(internal) ROGASANJEEVI THYLAM (EXTERNAL), OTTRADAM THERAPHY 
FOR THE STUDY OF UTHIRA VADHA SURONIDHAM.             
Fomentation is a type of heat external theraphy is applied to the skin to release swelling 
or pain so as to alleviate the deranged vadha disease by bringing in fresh energy by 
improving cutaneous circulation and neural conductivity. 
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AIM AND OBJECTIVES 
Aim:  
To Study  the safety and the therapeutic efficacy of Siddha medicine Rasa 
Chendhuram(Internal) and Roga sanjeevi thylam (External) and ottradam theraphy in 
“Uthira vadha Suronidham”(Rheumatoid arthritis) 
OBJECTIVE: 
Primary objective: 
     To study the safety and therapeutic efficacy of siddha medicine 
“Rasa chendhuram”(Internal) and Roga sanjeevi thylam(External) and ottradam 
theraphy in “Uthira vadha suronidham” (Rheumatoid arthritis). 
SECONDARY OBJECTIVE: 
1.To collect the various siddha literature and modern literature  regarding the disease
uthiravadhasuronidham (Rheumatoid arthritis) 
2.To use modern parameters to confirm diagnosis, severity of the disease and progress
of the disease. 
3.To explore the traditional preparations with  scentific evaluation of trial drug.
4.To evaluate the physico chemical analysis of siddha trial drug” Rasa chendhuram”.
5.To evaluate the pharmacological and safety standard of trial drug in animal models.
6.To evaluate the efficacy of the trial drug in Rheumatoid patients in terms of pain
assessment score before and  after treatment . 
7.To evaluate the therapeutiic efficacy of external theraphy Ottradam in Rheumatoid
patients. 
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8.To evaluate the safety parameters of the siddha trial drug in Rheumatoid patients in
terms of liver function and renal function test before and after treatment. 
AIM AND OBJECTIVES │2017
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REVIEW OF LITERATURE 
SIDDHA ASPECT 
Man according to siddha system is production of divine mind and thought 
produced essence of the five elements, sole of the stars, and the spirit which is the 
stellar and temporal sides of magnum limbus from the matrix of nature formed of 
seven layers of tissues. 
These five elements together constitute the human body and origin of other 
material objects are explained as Pancheekaranam (Mutual Intra Inclusion). None of 
these elements could act independently by themselves. They could act only in co-
ordination with other four elements. All the living creatures and the non-living things 
are made up of these five basic elements. The five basic elements form the connecting 
link between the Microcosm (Man) and Macrocosm (World). Any change in the 
universe due to natural or unnatural causes will create changes in human systems.  
“நிலம் நீர் தீ வளி விசும்ப ோடைந்துங் 
கலந்த மயக்கம் முலகமோதலின்” 
                           --ததோல்கோப் ியம் த ோருள் அகரோதி 
 Again it is said, like the universe man is composed of five elements such as 
earth, water, air, fire, ether. Therefore life force is the basis for man’s mental and 
spiritual activities on that nature may evolve him towards perfection. 
 The earth gives shape to the body and release Sits energy, Bones, muscles, and 
tissues represent if in the body. 
 Water makes the earth supple and helps in the transmission of energy, serum, 
lymph, saliva etc...Represent it in the body. 
 Fire makes the form of the body steady and gives vigour and stimulation. 
Digestion and circulation represent it in the body. 
 Air ignites the fire and works as a life carrier and is the support of all contact 
and exchange. Respiration and Nervous system represent it in the body. 
 Ether is the creator of life itself in the body .A harmonious combination and 
function of these elements in the body produce a healthy and beautiful life. 
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 THE 96 BASIC PRINCIPLES (96 Thathuvam)  
According to Siddha system of medicine, ‘Thathuvam’ is considered as a 
science that deals with basic functions of the human body. Siddhars described 96 
principles as the basic constituents of human body that include physical, 
physiological, psychological and intellectual components of an individual. These 
96Thathuvams are considered to be the cause and effect of our physical and mental 
well-being. The Thathuvam is the author of the conception of human embryo on 
which the theory of medicine is based. 
There are in our body several supports to the soul for the existence and 
sustenance of life and they are the five elements(Earth,water,fire,air,ether),the six 
plexus, the three humors(mukkuttram),72,000blood vessels and nerves etc.. 
Constituting in all 96 thathwas.i.e constitute principles in nature. These three humours 
(vatham, pitham, kabham) plays a major role in the body and their function remain in 
the balanced state in a normal healthy person and disturbance in their equilibrium 
leads to the development of diseases in the body. 
If the siddha medicine is to accomplish its real mission it must start a double 
movement of revival and reform. It must to revive its tridoshic theory on which the 
whole ancient medicine is based.  
முப் ிணிமருவிமுனிவுதகோள்குறிப்ட த் 
தப் ோதறியும்தன்டமயும்வோத 
 ித்தடவயம் ிரிடவயுமடவதோம் 
ஏறியிறங்கிஇனணந்துக்கலந்து 
மோறிமோறிவரும்தெயற்டகயோர் ிணி 
பநர்டமயறிந்துநீட்டுமருந்பத 
ெீரியதோதமனச்தெப்புவர்ெித்தபர 
                         --பநோய் நோைல் பநோய் முதல் நோைல் திரட்டு 
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  Man develops three distinct, personalities namely the mind and the vital or life force 
and the body .Through the mind he thinks and wills; through the vital or life force he 
executes his thought and will; through the physical body he expresses what he thinks 
and wills. The mind is vatha, vital or life force is Pitha, and the body is kabha. 
 Vatha, pitha, kabha have multiple significances and symbolical in terms. 
 Vatha represents Vayu, mind, dryness, pain, flatulence, sensitiveness, 
lightness, and also air. 
 Pitha represents gastric juice, bile energy heat, inflammation, anger and 
irritation, etc... 
 kabha represents feeling of cold ,heaviness, running of the nose, passing 
mucoid discharge and also the saliva. 
They are also formed by the combination of the five basic elements. Accordingly 
Vali is formed by the combination of Vali (Air) and Aagayam (Space). This is the 
Creative force. Azhal is formed by Thee (Fire). This is the Force of Preservation. 
Iyyam is formed by Mann (Earth) and Neer (Water). This is the Destructive Force. 
These three humours are in the ratio 4:2:1 in equilibrium which is a healthy normal 
Condition. They are called as the life forces or humours. 
 
THE FORMATION OF UYIR THATHUKKAL, 
 
The Valinaadi is formed by the combination of Abanan and Idagalai.  
The Azhalnaadi   is formed by the combination of Piranan and Pinkalai.  
The Iyyanaadi is formed by the combination of Samanan and Suzhumunai.  
 Vaatham - Ten types  
 Pitham - Five types  
 Kabam - Five types 
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(a) Five forms of vatha: 
     These are the five main centres of the subtle physical body and correspond to the 
nervous plexuses of the gross physical body. 
 Matedial of muladhar centre(அ ோனன்):This centre corresponds to the 
pelvic plexus and is the seat of kundalini or material energy and 
controls excretions 
 Navel centre (ெமோனன்): This corresponds to the solar plexus in the 
navel region and controls digestion. 
 Heart centre ( ிரோனன்): This refers to the cardiac plexus in the Heart 
and circulation. 
 ThroatCentre (உதோனன்): This corresponds to the pharyngeal plexus in 
the throat region and control breathing and speech. 
 Forehead centre (வியோனன்):This corresponds to the Naso-ciliary 
plexus at the root-of the nose and base of the skull and control “will” 
(b) Five forms of pitha: 
 Gastric juice ( ோெகம்): This give appetie and helps Digestion. 
 Bile ( ிரோெகம்): which gives complexion to the skin. 
 Haemoglobin (இரஞ்ெகம்): which colours the blood. 
 Aqueous Humour(ஆபலோெகம்):Which brightens the eyes 
 Life energy (ெோதகம்):Which  controls the whole body 
 (c) Five form of kapha: 
 Saliva(கிபலதம்):Which helps mastication 
 Cerebrospiral fluid(தற் கம்):Which  keeps the head cool 
 Lymph(ப ோதகம்):Which gives taste 
 Serum:(அவலம் கம்)Which helps the Heart in pumping 
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 Synovial fluid :(ெந்திகம்)Which lubricate and aids free movement of the 
joints 
        The three humours of vatha, pitha and kapha which are absorbed and circulated 
in the blood have each certain definite qualities:  What are they actually, 
1. VATHA. 
(Own qualities-6)-                                               (Opposite qualities-6)- 
Vatha is dry-வறட்ெி                     Unctuous- சுடம 
Vatha is cold-குளிர்ச்ெி                Hot-அக்கினி 
Vatha is subtle-அணூத்துவம்           Solid-தகட்டி 
Vatha is rough-கடினம்                     Soft-மிருது 
Vatha is unstable-அடெதல்               Stable-ஸ்திரம் 
Vatha is light-இலகு                 Heavy- ளுவு 
All this qualities are present in Air and hence air we inhale is Vatha 
2. PITHA 
(Own qualities-6)-                           (Opposite qualities-6)- 
Pitha is hot-அக்கினி                             Cold-குளிர்ச்ெி 
Pitha is acid-புளிப்பு                              Sweet-இனிப்பு 
Pitha is mobile- சுடம                            Immobile-நிடலதிருத்தல் 
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Pitha is liquid-ெலரூ ம்                            Solid-தகட்டி 
Pitha is acute-குரூரம்                              Mild or harmless-ெோந்தம் 
Pitha is pungent-கோரம்                             Bitter-கெப்பு 
All this qualities are present in the gastric juice and hence the gastric juice 
is pitha 
3. KAPHA 
(Own qualities-6)-                            (Opposite qualities-6)- 
Kapha is cold –குளிர்ச்ெி                           Hot-உட்டிணம் 
Kapha is heavy- ளுவு                             Lite-இலகு 
Kapha is immobile-அடெவின்டம                  Mobile-அடெதல் 
Kapha is sweet-இனிப்பு                            Pungent-கோரம் 
Kapha is soft-மிருது                               Rough-கடினம் 
Kapha is unctuous-ஈரம்                            Dry-வறட்ெி 
Kapha is viscid-வழவழப்பு                          Sandy-கரகரப்பு 
All this qualities are present in in Saliva so Saliva is Kapha 
VATHAM: 
The term Vatham denotes Vayu, pain, dryness and flatulence. Vaatham is responsible 
for respiration and control of all movements.  
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         Location -Abanan, faeces, Idakalai, Pelvic bone, spermatic cord, skin, nerves, 
joints, hairs and muscles.  
         Character -It governs the other two basic elements and responsible for all 
physical process in general. For this reason, disturbance in vatha tend to have more 
severe implication than the other two humours and other affect the mind as well as 
entire physical body and also responsible for respiration. 
         Functions -Pain in the whole body, twitching, pricking pain, inflammation, 
reddish complexion, and roughness of skin, hardness of limbs, astringent sense of 
taste in the mouth, constipation, and oliguria, blackish discolouration of skin, stool, 
urine and muddy conjunctiva. 
So for 4448 diseases are classified by Agasthiyar rathina surukkam naadi, 
and in this Vatha diseases are classified as 84 types 
நோளைோ நோற் த்து நோலு நூறு 
நயமுைபன நோற் த்து எட்டு பரோகம் 
 ோரப் ோ வோதமது எண் த்து நோலு. 
Vatham or vali is not mere wind, but also that causes motion, energy, and 
sensation of every cell in the body. vali relates to the nerve force. It is responsible for 
all movements in the mind and the body. 
In human body the locomotors activity functions through voluntary muscles 
and its activities controlled by nerves system called Kanmendhriyam, likewise the 
sensation and its activities are known as Gnanendhriyam. These types of activities are 
governed by valikutram among the mukkutram. 
LOCATION OF VATHA HUMOUR: 
 Below the navel region (umbilicus) 
 Urinary bladder, motion, Spermatic cord, Umbilical cord, thigh, bone, skin, 
nerves, joints, muscles, hair follicles, pelvis, ear. 
 வோதத்தின் இருப் ிைம்: பெருங்குடல். 
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NATURAL PROPERTIES OF VATHAM: 
ஒழுங்குைன் தோபதழ் மூச்பெோங்கி இயங்க 
எழுச்ெித ற எப் ணியு மோற்ற எழுந்தரிய 
பவகம் புலன்களூக்கு பமவச் சுறுசுறுப்பு 
வோகளிக்கும் மோந்தர்க்கு வோயு. 
                       -மருத்துவ தனி  ோைல்,ெித்த மருத்துவோங்க சுருக்கம் 
                                                       க்கம்-140 
 Functioning of mind throughout the body 
 Giving briskness 
 Making the uniform functioning of seven udalkattugal 
 Protection and strengthening of five sensory organs. 
 Regulation of fourteen physiological reflexes. 
QUALITIES OF VATHAM: 
வோதங் கடுடம வறட்ெியுைன் தநோய்டம 
ெீதமுஞ்ச் ெலனம் ெிதறணுவு ஏதமுை 
னிக்குணத்பதோடுற் பறயியக்கந்த ருமளவிற் 
தக்க  ரிகோரந்தோ. 
                          -கண்ணுெோமியம்- க்கம்-21 
(Own qualities-6)-  
Vatha is dry-வறட்ெி 
Vatha is cold-குளிர்ச்ெி 
Vatha is subtle-அணூத்துவம் 
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Vatha is rough-கடினம் 
Vatha is unstable-அடெதல் 
Vatha is light-இலகு. 
வோத குணமோறுக்கு மோறுகுணபம பனோக்கின் 
ஒதமிரு தீரம் உயிர் ோரம் ப ரோதரவோ 
யுள்ள தீபயோடுறதி யியற்றுத் திரளோக 
உள்ள குணத்டதபய யூட்டு. 
                        -கண்ணுெோமியம்- க்கம்-22 
(Opposite qualities-6)- 
Unctuous- சுடம 
Hot-அக்கினி 
Solid-தகட்டி 
Soft-மிருது 
Stable-ஸ்திரம் 
Heavy- ளுவு 
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VARIETIES OF VATHAM: 
முடறயோம்  ிரோணபனோை  ோனன் வியோனன் 
மூர்க்கமோ முதோனதனோடு ெமோன னோகும் 
திறடமயோங் கூர்ம் தனோடுகிருகிர ன்றோன் 
பதவத் தபனோடு தனஞ்தெயனு மோகும். 
                               - ெித்த மருத்துவோங்க சுருக்கம்  க்கம்-142 
VAAYU – 10 (VITAL NERVE FORCE WHICH IS RESPONSIBLE FOR ALL 
KINDS OF MOVEMENTS)  
 
1. Uyirkaal (Piraanan)  
 
        This is responsible for the respiration of the tissues, controlling knowledge, mind 
and five sense organs and digestion of the food taken in.  
 
2. Keel nokkukaal (Abanan)  
 
        It lies below the umbilicus. It is responsible for the downward expulsion of stools 
and urine, ejaculation of semen and menstruation.  
 
3. Paravukaal (Viyanan)  
 
       This is responsible for the motor and sensory function of the entire body and the 
distribution of nutrients to various tissues. 
 
4. Maelnokkukaal (Uthanan)  
 
      It originates at Utharakini. It is responsible for digestion, absorption and 
distribution of food. It is responsible for all the upward movements.  
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5. Samaanan (Nadu kaal)  
     This is responsible for the neutralization of the other 4Valis i.e. Piranan, Abanan, 
Viyanan and Uthanan. Moreover it is responsible for the nutrients and water balance 
of the body.  
 
6. Naagan 
     It is a driving force of eye balls responsible for movements. 
 
7. Koorman 
     It is responsible for the opening and closing of the eyelids and also vision. It is 
responsible for yawning.  
 
8. Kirukaran 
    It is responsible for the salivation of the tongue and also nasal secretion. 
Responsible for cough and sneezing and induces hunger.  
 
9. Devathathan 
   This aggravates the emotional disturbances like anger, lust, frustration etc. As 
emotional disturbances influence to a great extent the physiological activities, it is 
responsible for the emotional upsets.  
 
10. Dhanancheyan 
     Expelled three days after the death by bursting out of the cranium. It is responsible 
for edema, plethora and abnormal swelling in the body in the pathological state. 
 
As per yugi  vaithiya  chindhamani 
 
............................................................ 
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AETIOLOGY OF VATHA DISEASES: 
According to Yugi vaithiya chinthamani 
 
“  
 
 
 
 
 
 
 
 
 
 
                     
 
 
 
                    
 Excessive sexual indulgence 
 Over consumption of bitters, 
astringents and rancid foods. 
 Drinking rain water 
 Day time sleep 
 Night time work 
 Starvation 
 Lifting over weight 
 Will initiate and aggravate vali 
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As per“Konganavar Vatha  Kaviyam” 
                       “  
                          
              
                       
                          
          
      
                        
    
   
 
            
            
 
 Excessive exposure to the sun 
 Excessive intake of water 
 Postponed  of proper intake of food 
 Excessive intake of bitter gourd 
 
 
According to Agathiyar Kanma Kaandam 
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 cutting trees and barks 
 Breaking the legs of living animals 
 cutting the leaves of living trees 
 
According to Agathiyar Gunavagadam, 
 
அம்புவியில் வோத பனோய் வருகும் பநர்டம 
அப் பன தெோல்லி கிபறன்றி வோய்க்பகளு 
அறுகுமைோ மோமிெத்தின் வியோதி யோலும் 
அப் பன சூதகத்தின் த ருக்கோலும் 
குடிதகடுத்த வோதமது உண்ைோ மப் ோ. 
 
 Muscular diseases 
 Menorrhagia 
 Consumption of improper preparation of metallic compounds like mercury and 
lead will cause vatha diseases 
 
CHARACTERISTICFEATURES OF VATHADISEASE: 
 
1. As per Theraiyar Vaagadam: 
              
 
 
   
 Loss of appetite 
 Pain and redness 
 Fever and cough 
 Insomnia 
 Shivering 
 Hyper  pyrexia 
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Chillness of the body  
 Rigor and spasm 
 Pain and tenderness of joints 
 Swelling of the joints. 
    அறியதிம் மூன்றின தோண்டம தெோன்னோர் னநந்தி 
 றிதயன தநோந்து மற் ச்டெ புண்ணோகும் 
                                                              -திருமூலர் நோயனோர் ெிகிச்ெோ ரத்ன தீ ம் 
 
 Pain in the upper and lower limbs, pain in the costochondral junctions will 
be seen in vatham diseases. 
 
வோதம் வந்துற்றப ோது வயறது  த ோருமி  தகோள்ளும் 
............................வந்த  வோதத்தின்  குணமிதோபம 
                                                        -யூகி முனிவர் த ருனூல் டவத்திய  கோவியம்(1000) 
 
 When vatham increases it produce abdominal discomfort, pain in the hip 
joint and all the joints of upper and lower limbs, constipation and painful 
voiding of urine and stools will be seen. 
 The diseases will be precipitated in months from aani to karthigaii.e.,from 
June to December,(muthuvenil,kaar,andkoothirkaalam) 
 
 கரபவ வோதமது பகோ ித் தப்ப ோ 
 ண் ோக த ண் ப ோகமது தோமன் தெய்யில 
...........................கடனக் கோலும் கடுப்பு உண்ைோபம 
                                                      -யூகி டவத்திய ெிந்தோமணி ோைல்-285 
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 Indulging in sexual act during vitiation of vatham 
 Walking for long distance 
 Exposing to cold and dampness and harmful combinations like fruits 
vegetables and tubers with curd ,causes toxic factors which affects bones 
and joints 
 In Aaviyalikkum Amutha murai Surukkam 
 
   
    
  
                       
  
                       
          
         
 Fatigue, tiredness 
 Nausea  
 Loss of appetite 
 Pricking sensation all over the body 
 Pain all over the joints. 
 Diarrhoea 
 Azoospermia 
 Incontinence of  urine 
 Difficulty  in flexion and extension 
 Constipation 
 
Agathiyar2000 
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 Giddiness 
 Redness of eyes 
 Stabbing pain in the face 
 Abdominal distension 
 Joint pain in upper and lower limbs 
 Numbness in the limbs 
 Oliguria 
 Drowsiness 
 Chillness of the body 
             
 
 
 
 
 
 Pain in the joints 
 Head ache 
 Excessive yawning 
 Constipation 
 Burning sensation of the body 
 Paralysis 
 Excessive salivation 
 Chillness and tremor 
 
 
Inkaviyanaadi 
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UTHIRAVATHA SURONITHAM 
 
“UTHIRAVATHASURONIDHAM” is one among the eighty types of vatha 
diseases described by the great siddha pathologist yugi munivar in the textbook of 
“YUGIVAIDHYA CHINTHAMANI”. 
A form  of  arthritis  of  rheumatic  origin  marked  by  severe  pain  and  the formation  of  
inflammatory  nodules  in  the  region  of  the  joints  and  especially  in the limbs of the body. 
 
According to kathirai  velpillai  tamil  mozhi  agarathi 
 
சுர ோணிதம்-உதிரம் 
உதிரவோதம் 
According to sambasivam  pillai  dictionary 
 
      
 
 
சுர ோணித வோதம்: 
A disorder  of menstruation in women marked by affection in the chest and 
limbs extreme sensibility to pain, dryness in the dendrites nervous shock, accompanied 
by intense body pain. 
 
Therayar  vaagadam: 
 
 
 
      ( ிரிவிடை- த ண்ணின்மத்திய ருவம்-) 
 
The disease “suronithavatham” is occurs in the middle aged women. 
 
                    “  
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Vitiation of vatha aggravates the signs and symptoms of “vathasuronitham”. 
 
Jeeva raksha mirtham classifies this disease into two types, 
 
 Pitha sonitha vatha rogam, which is soft and cause emaciation. 
 Slethuma sonitha vatha rogam has polyarthralgia and spindle shaped 
swelling in the phalanges. 
 
Siddha pathology: 
கோணப் ோ வோத மீறில் கோல்டககள் த ோருத்து பநோகும்.............. 
தெோல்லபவ வோதமது மீறிற் றோனோல் 
பெோர்வடைந்து வோயு வினோல் பதகதமங்கும் 
தமல்லபவ டககோல் களெிக லுண்ைோகும் 
தமய்முைங்கும் நிமிர தவோண்ணோ  திமிருண்ைோகும் 
                                                                     -அகத்தியர் 
வளிவோக நோலோயிரத்து நோனூற்று நோற் த்ததட்டு 
வந்தணுகில் ததகமதில் வலுவியோதி 
                          -அகத்தியர்  
எரியநல் வோத தமறிக்குங்வ குணங்பகளு 
குறிதயனக் டககோல் குளச்சு விலோச் ெந்து 
                        --பநோய் நோைல் பநோய் முதல் நோைல் திரட்டு 
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Nadi pathology: 
திருந்துமோம் வோதத் பதோபை தீங்தகோடு ித்தஜ்பெரில் 
த ோருத்துகள் பதோறும் தநோந்து 
                                                    -குணவோகைம் பநோயின் ெோரம் 
 
AETIOLOGY OF SURONITHA VATHAM 
 
 
 
 
 
 
 
 
 
 Intake of spicy food stuff 
 Intake of astringents 
 Daytime sleep 
 Sedentary life 
 Food which decrease the absorption of iron 
 Foods which increases the body heat. 
 Riding over the  elephant  and horse 
All these factors will affect vatha which along with blood produces Suronithavatham. 
 
According to para rasa sekaram: 
 
 
 
 
 
 Over conception of bitters, astringents , savouries and rancid foods 
 Intake of cold water 
 Intake of varagu ,thinai 
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 Eating of excessive intake of  food 
 Starvation 
 Excessive sexual indulgence 
 Sleeping in  the day time &not sleeping in the night 
 Not taking food at proper time, Decreased  intake of sour and ghee diet  
increase  The vatham 
 
 
 
 
 Fear 
 Anger 
 Worry 
In textbook of siddha medicine (sabaa pathy kaiyedu) 
 
 
                    
 
o Intake of  vatham containing food stuffs 
o Intake of cold items 
o Exposure to extreme cold air, rain, and snow 
o Hereditary 
o Stay in mountain 
 
 
 
 
 
 
 
 
026
                                                                                             REVIEW OF LITERATURE│2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
CLINICAL FEATURESOF UTHIRAVATHA SURONITHAM: 
 
In yugi vaithiya chindhamani 
 
                     
                     
                      
 
                     
 
 
 Swelling of the ankle and knee joints 
 Swelling of the foot 
 Pain in the fingers and toes 
 Confusion 
 Fatigue 
 Loss of appetite 
 
In Dhanvandhiri vaithiyam 
 
                      
 
 
 
 
 
o Pyrexia and swelling of the body as in rat poison intoxication 
o Pain and tenderness 
o Twitching of muscles 
o Loss of sensation 
o Swelling of the wrist and phalanges 
o Black and redness of swelling due to vascular failure 
o Hyperaemia 
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According to Vaithiya Chindhamani by kannusamy 
 
 
 
 
 
 The disease name suronitha vaatham is also mentioned in  
       Aaviyalikkum 
 Amuthamurai Churukkamas painful and swollen joints. 
 Anubogavaithiya Deva Ragasiyam also deals with vatha diseases. 
 Instead of “Uthiravaatha suronitham”itis mentioned as 
 “Sonithavaatharogam”. 
 Jeevarakshamirtham also deals it as sonithavaatharogam in 
Vaatharogapadalam and the symptoms are polyarthralgia, swelling, 
anaemia, spindle shaped swelling in the joints. 
 
Inpararaasasekaram 
 
 
 
 
Decrease in the haemoglobin level 
 Pain in the upper and lower limbs 
 Swelling especially in the peripheral joint and deformities 
 Morning stiffness present more than 1 hr. 
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 Swelling of the ankle and knee joint 
o Swelling of hind foot 
o Pain in the distal interphalangeal joint 
 
According to Agathiyar Ayulvedham– 1200 
 
 
 
 
 
Pain in the upper and lower limbs, forehead and cervical region. Restricted joint movements. 
 
DIFFERENTIAL DIAGNOSIS: 
 
Among the 80 types of vaatha diseases mentioned in“yugivaithiyasindhaamani” the 
“Uthiravaathasuronitham”is differentiated from the following types of suronitham 
 
வோத சுபரோணிதம்: 
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o Emaciation 
o Swelling of joints 
o Restriction of movements 
o Anorexia 
o Excessive  salivation 
o Discomfort 
 
 
     
 
 
 
o Anasarca 
o Reduced haemoglobin  level 
o Wrinkles 
o Neural pain 
o Bullus eruption as in palms 
o Glossy tongue 
o Sialorrhoea 
o Exfoliation, swelling and 
o Warmness. 
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o Swelling with hyperaemia 
o Soft on touch 
o Cough 
o Pyrexia 
o Irritability 
 
            
           
           
           
o Hyperaemia 
o Tenderness in knee, elbow and smaller joints 
o Polyarthralgia 
o Pyrexia 
o Anaemia 
 
 
 
 
 
 
 
o Chillness with abdominal distension 
o Severe pain 
o Head ache 
o Bronchitis with dyspnoea 
o Giddiness 
o Dryness of mouth 
o Tachycardia 
o Syncope and Hallucination 
o Anorexia 
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o Fever with rigor 
o Dryness of mouth 
o Diarrhoea 
o Headache and giddiness 
o Excessive thirst 
o Loss of appetite 
o Pain all over the body 
 
IN SIDDHA MODE OF PATHOLOGY 
 
 Vatham is said to be phenomenon responsible for the movements of the parts 
involved in locomotor system, hence it is responsible for the articulation of the 
joints, tendons and muscles. 
 Bone and lower abdomen is considered to be the place for vaatham. 
 Santhiga kabam is said to be the phenomenon which is responsible for the normal 
maintenance of synovial fluid. 
 Synovial fluid provides nutrition for the articular cartilages, disc ,meniscus and 
thereby  avoids friction of the bones and erosion of the bones, it helps the smooth 
articulation. 
 In Uthiravathasuronitham due to factors related to diet, habit, environment etc, 
adversely influence of vali and azhal mainly in mukkutram 
 The involvement of viyanavayu and abanavayu plays a major role in the 
manifestations of signs &symptoms.  Viyana is responsible for all the motor and 
sensory functions of the body and the nutrition of tissues. 
 Abananvayu is responsible for the assimilation of the nutritional factors from the 
gastro intestinal tract distribution between various thathus and expulsion of waste 
product through faeces, urination etc... 
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AZHAL: 
 The azhal is responsible for the healthy maintenance of every tissue of the body and 
its variation results in inflammatory changes in the bone and other accessory 
structures like tendons, cartilage and synovial membrane which helps in perfect 
articulation of joints. 
 
IYAM : 
 The deterioration of iya humour leads to structural changes in the bones and the 
fluids in the joints which are mainly controlled by the factors of santhigam. 
 Disturbance in humours it produce different clinical manifestations. They 
Include, 
 Swelling of the joints, 
 Pain 
 Stiffness 
 Restricted movements of the joints due to disturbed vali. 
 Inflammatory changes of the joints like redness hyperaemia, and warmness due to 
disturbed azhal and erosion of bone margin, increased synovial fluid due to 
disturbed iyam. 
 The tridosha phenomenon and the functioning of the joints, 
 
வளிமிகு வ ோன வியோன வோயுக்களதிகரிக்கும் 
இளமிகு மலனரீ்க் கட்டும் இயம் ிய வ ோனன் தெய்யும் 
வளிவிலோ வியோனன் கீலின்விளங்குறு புடழகப ோறும் 
ஒளியுறு குற்றதமல்லோ தமோன்றிதலன்று லவச்தெய்யும். 
                               ெ ோ தி டகபயடு-ெித்த மருத்துவம், க்கம்-603 
 UYIRTHAATHUKKAL: 
 These are the fundamentals and essential factors in the composition and constitution 
of the human body. 
 Vaatham(vali) 
 Pitham(azhal) 
 Kabam(iyyam) 
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PINIYARI MURAIMAI-(DIAGNOSIS): 
            The methodology of diagnosing in siddha science is very unique and solely based on 
the clinical acumen of the physician. 
It is based on the three main principles, 
   1. PORIYAL THERTHAL 
   2. PULANAL THERTHAL 
   3. VINATHAL 
 
1. PORIYAL THERTHAL: 
  Pori means sense of perception. Poriyaltherthal understands by the five sense organs such as 
nose, tongue, eyes, skin, and ear. 
 
2. PULANAL THERTHAL: 
Pulan means objects of senses. Pulanaltherthal understands by the sense objects. 
1. Smell (Manam) 
2. Taste (suavai) 
3. Vision (oli) 
4. Somatic sense (ooru) 
5. Sound (oosai) 
In both of the above said methods, physician, pori and pulan are used as tools for examine the 
pori and pulan of the patients. 
 
3. VINATHAL: 
Vinathal is the process of obtaining the detailed history of the disease by interrogation the 
patient. By this gathering the history of disease, complaints, and duration, personal history, 
family history, clinical features, where an accurate history, is available, a disease can be 
easily diagnosed ever before clinical examinations carried out. It is the focal point of the 
“physician –patient” relationship and established the bonding necessary for patient cure. 
 The classified method of clinical examinations is known as ENVAGAI THERVU, 
Siddhars have devolved a unique method of diagnosing the diseases by “ENVAGAI 
THERVU” eight basic diagnostic parameters namely, 
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 Sparism 
 Naa 
 Niram 
 Mozhi 
 Vizhi 
 Malam 
 Moothiram 
 Naadi 
 
NAADI NADAI IN UTHIRA VATHA SURONITHAM: 
Naadi diagnosis is the confirmatory diagnosis, Naadi is the inherent seat anchor of energy on 
which vibration the entire thathus of the body are functioning. 
1. Vathakapham 
2. Kaphavatham. 
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Derangements of vatham in uthiravathasuronitham: ` 
 
Abhanan: Constipation, polyuria, menstrual 
Viyanan:  Pain and tenderness in the affected joints 
Samanan:  Affected due to the derangements 
Koormam:Extra articular features 
Kirukiran: Loss of appetite 
 
Derangements of pitham in uthiravathasuronitham: 
 
Analagam:  Loss of appetite 
Ranjagam: Anaemia 
Saadhagam: Disturbances in regular activities 
Aalosagam: Disturbances in vision 
Prasagam:   Redness 
 
Disturbances of kabham in uthiravathasuronitham: 
Avalambagam: Dyspnoea (due to anaemia) 
Kiledham: Loss of appetite 
Sandhigam: Restriction of joint movements 
Udalthathukkal: 
In uthiravathasuronitham cases, 
Saaram 
Senneer 
Oon 
Kozhuppu 
Enbu 
Moolai 
Are the most affected 
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Gnanendhiriyam: 
In uthiravathasuronitham cases, 
Mei: Pain and tenderness in the joints 
Kan: Disturbances of vision (scleritis) 
 
Kanmendhiriyam: 
In uthiravathasuronitham cases, 
 Kai  : Difficulty to use the upper limbs  
 Kaal: Difficulty to use the lower limb  
 Eruvai: Constipation in some cases 
 Karuvai: Irregular menstrual cycle in some cases 
 
PININEEKAM: 
Siddha system of medicine is a unique system of medicine in which treatment is given 
both for the body and mind. Thiruvalluvar in his thirukural under the heading 
“MARUNDHU” mentions about the diseases and its prevention, they are, 
So in Siddha system, treatment is not only for the removal of diseases, but for prevention and 
improving the body condition-Rejuvenation. 
1. Prevention 
2. Treatment-curative 
3. Restoration-promotive 
 
1. PREVENTION: 
  It is very much, essential and stressed in all siddha literature. Body and mind should 
be very clean and free from evil thoughts and deeds. 
2. TREATMENT: 
     A Good physician should know about the derangements of humours and should 
treat the patients on the basis of altered humours. 
Treatment is based on, 
To bring the tridosham to normal 
To treat the disease according to its symptoms through medicines, 
To increase the natural immunity 
To normalize the tridosham, 
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விர சனத்தோல் வோதம் தோழும் . 
Vatha disease can be brought down by vireasanam(purgation),by giving the laxatives and 
purgatives according to the patient conditions, Four requisites of successful treatment are 
explained by “THIRUVALLUVAR” 
 
உற்றவன் தீர்ப் ோன்மருந்துடழவச் தெல்வோதனன் 
றப் னோறகூற்பற மருந்து. 
 
RESTORATION: 
 
 Reassurance is given to all the patients for fast recovery 
 Not to be anxious 
 Not to be depressive 
 Avoid exposure to cold 
 Avoid excessive workload 
 To advice the patients to do asanas regularly  
 
MANEGEMENT OFUTHIRAVATHASURONITHAM: 
  
       The treatment of siddha medicine is aimed at keeping the three humours in 
equilibrium and maintenance of seven elements. So proper diet, medicine and 
disciplined regimen of life are advised for the healthy living and to restore equilibrium 
of humours in diseased condition. 
 
INTERNAL MEDICINE: RASACHENDHURAM 65mgwith honey twice daily, after 
food for the period of48 days. 
EXTERNALMEDICINE:   ROGA SANJEEVI THYLAM with OTTRADAM 
THERAPHY. 
 
038
 JOINTS : 
 Joints are mainly classified structurally and functionally. structural classification is 
determined by how the bones connect to each other ,while functional classification is 
determined by the degree of movement between the articulating bones. 
There are three structural joints are, 
1 .Fibrous joints-joined by dense regular connective tissue that rich in collagen fibres 
2.Cartilagenous joints-joined by cartilage. 
3.Synovial joint-the bones have synovial cavity. 
       Joints  are sites where two or more bones of the skeleton or cartilages articulate.It 
admits more or less motion of one or more bones is termed as a joint.The articular 
surfaces of bones  are  covered by hyaline cartilage which is thicker in weight bearing 
areas than in non weight –bearing  joint. 
The joints can be classified functionally ; 
1.Diarthrodial or synovial joints with a joint cavity 
2.synarthrodial or nonsynovial joints without a joint cavity 
3.Amphiarthrosis-cartilagenous joints,permits slight mobility. 
Synarthroses ( solid joints)are commonly grouped according to the principle 
type of interosseous connective tissue into fibrous joint and cartilaginous joints. 
Disarthrosis (cavitated joints) between the ends of other circumscribed surface 
of endochondrial bones.   
Most of the diseases of joints affect diarthrodial or synovial joints.In 
diarthrodial joints, the end of two bones are held together by joint capsule with 
ligaments and tendons inserted at the outer surface of the capsule.The joint space is 
lined by synovial membrane  or synovium which forms synovial fluid that lubricates 
the joint during movement. 
There basic structures of synovial joints  are followed, 
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1.CAPSULE- It is  made of tough membrane enclosing the joint.It connects the bone
and holding them firmly in place. 
2.Articular cartilage- It is composed of collagen and proteoglycans and 65.80% water 
which forms the cartilage matrix. And  it is covering the end of the bones ,absorbing 
the shock while providing a slick surface so that the bone ends can easily glide across 
each other during movement. 
3.Synovium- It secretes the synovial fluid  to lubricate and nourish the cartilage
4.Muscles- It act as a shock absorber and contracts to provide a movement. 
5.Ligaments- It attaches bone to bone and provide stability. 
6.Tendons- It attaches muscles to bones and acts as a secondary joint stabilizer and 
also allow for free movements. 
7.Bursae- It is sac like cavity situated in places in tissues to facilitate the gliding of 
muscles or tendons over bony or ligamentous surfaces.And protecting them against 
friction ,wear and tear. 
CLASSIFICATION OF SYNOVIAL JOINTS: 
1.Plane joints 
2.Hinge joints 
3.Pivot joints
4.Bicondylar joints 
5.Ellipsoid joints 
6.Saddle joints  
7.Ball and socket joints 
Syndesmosis: 
The articulating  bones are kept at a distance but united by a strong ligaments.e.g 
vertebral arches ,coracoids process, and clavicle. 
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Nerve supply: 
The sources of nerve fibres to a joint conform well to Hilton’s law- the nerves to the 
muscles acting on a joint as well as to the skin over the area of action of these 
muscles.The capsule and ligaments receive an abundant sensory nerve supply. 
Blood supply. 
The articular and epiphyseal branches of neibhoring arteries form a peri articular 
arterial plexes 
The articular capsule is higly innervated but avascular (lacking blood and lymph 
vessels),and receives nutrition from the surrounding blood supply.The synovial 
membrane is higly vascular and lymphatic. 
Diseases of joints and their classification: 
1.Infective arthritis: 
Bacterial,viral.and parasite 
a.Acute infection: 
 Acute pyogenic arthritis
 Acute gonococcal arthritis
 Acute rheumatic arthritis
 Small pox arthritis
b.Chronic infection: 
 Non-specific: Pyogenic arthritis
 Specific:Tuberculous arthritis,syphilitic arthritis,gonococcal arthritis
 Parasitic:Guinea worm arthritis
2.Rheumatoid arthropathy
 Rheumatoid arthritis
 Juvenile rheumatoid arthritis
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b.Seronegative spondyloarthropathy
 Ankylosing spondylitis
 Reiter’s disease
 Psoriatic arthritis
 Enteropathic arthritis
3.Degenerative arthrosis(orteoarthritis) 
 primary orteoarthritis
 secondary orteoarthritis
4.Neuropathic   arthrosis 
 Charcot’s arthropathy
 Syringomyelia
 Leprosy
 Diabetes mellitus
5.Metabolic arthritis
 Gout
 Pseudo- gout
 Alkaptonuric arthritis
6.Arthritis in system disorders 
 Haemophilic arthritis
 Reactive arthritis
7.Miscellaneous conditions
 Villonodular synovitis
 Synovial chondromatosis
8.Hysterical joints. 
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Arthritis is a generic term for inflammatory joint disease. With the involvement of 
synovium, articular surfaces, and capsule.The inflammation may be such a severity as 
to destroy the joint cartilage 
AUTO IMMUNE DISEASE: 
Auto immune disease affects up to 50 million americans ,according to the 
American  Autoimmune Related diseases association (AARDA).The immune system 
contains a complex organization of cells and antibodies  designed normally to “seek 
and destroy”invaders of the body ,particularly infections .Patients have antibodies and 
immune cells in their blood that target their own body tissues ,where they can be 
associated with inflammation, while inflammation of the tissue around the joints and 
inflammatory arthritis  are characteristics feature of rheumatoid arthritis.  
An auto immune disease devolps when your immune system  which defends 
your body against disease decides your healthy cells are foreign .As a result your 
immune system attack healthy cells and your immune system produces antibodies 
(proteins that recognize and destroy specific substances ) against harmful invaders in 
your body . 
 The cause of auto immune disease like bacteria or virus ,drugs ,chemical 
irritants environmental factors. The most common symptoms are  fatigue,fever,general 
malaise Symptoms worsen during flare –ups and lessen during remission.It mainly 
affects  the joints  in the hand ,wrists,knees and interphalangeal joints are typically 
inflamed in a symmetrical distribution and linning of joints become inflamed causing 
damage to joint damage  
 RA can also affects other tissues throughout the body and cause problems in 
organs such as the lungs,heart,and eyes. 
RHEUMATOID ARTHRITIS: 
It is generalised chronic multisystem disease affecting the connective tissues  of 
the whole body with focalized involvement of musculoskeletol system.Though the 
most prominent manifestation of RA is inflammatory arthritis  of the peripheral joints 
usually with symmetrical distribution  followed by pain, swelling, stiffness, of the joints 
especially involving  joints of hands, wrists and feet and later on spread to the proximal 
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 joints such as the knee, hips, elbow, shoulder. It is considered to be an auto immune 
response to an unknown antigen and the antibody formed is the rheumatoid factor which 
is identified as immunoglobulin M autoantibody is directed against the Fc portion of 
IgG antibodies. 
Epidemiology of Rheumatoid arthritis: 
RA is a common chronic disease that affects about 1% of the world population. The 
prevalence of RA  in the united states, based on rates of RA from 1995 minnesota study 
and 2005 census data is currently estimated at approximately 1.3 million people or 0.6% 
of the population according to  current census data. In india the prevalence of the disease 
0.75% projected to the whole population, this would give a total of about seven million 
patients in india. 
The diseases is 3-5 times highly prepondarence in females than in males. The disease 
can begin at any age and even affects children (juvenile idiopathic arthritis),but it most 
often  starts after 40 years of age and before 60 years of age .The courses and severity 
of the illness can vary considerably. Around 80% moderately to severly disable within 
20 years ,around 40%of RA patients registered disabled within 3 years and 25%will 
require a large joint replacement. 
The risk of RA may be highest  when people with these genes HLA DR1, DR4 and 
MHC  class 2 familial aggregation.cigratte smoking increases a person’s risk of 
devolping  RA and can make the disease worse. 
Women who have never given birth  may be at greater risk of devolping RA.Obesity 
also increase the risk of devolping RA.But the women who have  breastfeed their infants 
have a decreased risk of devolping RA. 
Etiopathogenesis: 
   Present concept on etiology and pathogenesis proposes the RA occurs in an 
immunogenetically predisposed individuals  to the effect of microbial agents acting as 
trigger antigen.The role of superantigens which are produced by several micro 
organisms with the capacity to bind to HLA-DR molecules(MHC-II REGION) has also 
emerged 
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  1.Immunologic derangements 
        Detection of circulating  autoantibody called rheumatoid factor(RF)against Fc 
portion of autologous IgG in 80%cases of RA. 
The presence of antigen antibody complexes(IgG-RF)in the circulation as well as in 
synovial fluid  
Antigenecity of proteoglycans of human articular cartilage.Association of RA with 
amyloidosis. 
The presence of other autoantibodies such as anti nuclear factor(ANF) antibodies to 
collagen type II  and to cytoskeleton. 
Activation of cell mediated immunity as observed by presence of numerous 
inflammatory cells in the synovium, chiefly CD4+T Lymphocytes and some 
macrophages. 
2.Trigger events: 
  It initiate the destruction of articular cartilage.The existence of an 
infectious agents such as mycoplasma,Epstein –Barr virus(EBV),cytomegalo 
virus(CMV). 
      The possible role of HLA-DR4 and HLA-DR1 in initiation of immunologic 
damage.CD4+T –Lymphocytes are activated.These cells elaborate cytokienes ,the 
important being Tumour necrosis factor(TNF)- ,Interferon(IF) ,interleukin (IL-1,IL-6). 
Activation of B –cells releases IgM antibody against IgG-Rheumatoid factor.IgG and 
IgM immune complexes damage to the synovium,small blood vessels,and collagen. 
Activation of macrophages release more cytokienes which cause damage to joint tissues 
and vascularisation of cartilage termed PANNUS formation.And eventually destruction 
of bone and cartilage are followed by fibrosis and ankylosis producing joint 
deformities. 
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 CHART NO. 3.1 : IMMUNOLOGY OF RA 
Genetic predisposure: 
The condition have high associated with class II major histocompatibility complex 
allele HLA-DR4,HLA-DR1 and familial aggregation. 
Abnormal immune response: 
    Immune mediated response to infections caused by mycoplasma ,Epstein –Barr virus 
,cytomegalo virus ,parvo virus in a genetically predisposed individual. 
Morphological features: 
    The predominant pathologic lesions are found in the joints, and tendons,and less 
often extra articular lesions are encountered. 
Effects of pregnancy on RA: 
       Pregnancy alters the immune state ,possibly contributing to a change in the course 
of RA.For decades, the ameliorating effects of pregnancy on the disease activity in 
women with RA have been observed. 
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 Pathogenesis: 
  Rheumatoid  disease is considered to be an auto immune response to an unknown 
antigen and the antibody formed is the rheumatoid factor which is identified as 
immunoglobulin M antibody directed against the Fc portion of IgG antibodies present 
in about 80% patients  and important prognostic factor.Also present in the following, 
Sjogren’s syndrome 
Systemic lupus erythematosus 
Sarcoidosis 
Tuberculosis 
Other autoantibodies also present in rheumatoid arthritis-Antifilaggrin and Anti 
citrullinated proteins   
      CHART NO. 3.2 : JOINT AFFECTED BY RA 
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 PATHOGENESIS OF RA: 
 Inflammatory reactions 
Collagen bundles are disturbed 
↓ 
          Hyperaemia devolps 
↓ 
              Aggregation of leucocytes into joint space 
↓ 
             Leucocytes organised in to granulation tissue 
↓ 
     Granulation  tissues matures  and to form granular pannus  
↓ 
       Granular pannus produce one enzymes called lysozymes 
↓  
  Lysozyme enzymes destroy the articular &peri-articular cartilage      
↓ 
The process  is end with  Ankylosis. 
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 Stages of rheumatoid arthritis: 
The diseases follows  three stages , 
1.Synovitis
2.Destruction
3.Deformities
1.First stage-Synovitis:
      Rheumatoid  arthritis is an inflammation of the synovial membrane,which become 
oedematous, and thickened with inflammatory exudates.The joint inflammation of RA 
causes swelling ,pain,stiffness,and redness in the joints. Chronic  persistent  synovitis 
is a characteristics feature of RA. Initial lesion occurs in the synovium ,leading on  to 
vascular stasis , infilteration of the subsynovial  layers with inflammatory cells. 
2.Secondary stages:Destruction: 
   In the later stage ,the synovium become more vascular and throws a fibrinous 
exudates which get organised into a granular tissue and spreads over the articular 
cartilage as the pannus. 
Histologically, the characteristics features is diffuse proliferative synovitis with the 
formation of pannus.The microscopic changes are as under; 
      1.Numerous folds of large villi of synovium. 
      2.Marked thickening of the synovial membrane due to oedema ,congestion,and 
multi layering of synoviocytes. 
3.Intense inflammatory cells infilterate in the synovial membrane with
predominance of lymphocytes,Plasma cells and some macrophages at places forming 
lymphoid follicles forming nodules with scattered cells. 
     4.Foci of fibrinoid necrosis  and fibrin deposition. 
  The pannus which encroaches the articular cartilage from its periphery.It 
progressively destroys the underlying articular cartilage and subchondral bone.The 
invasion of pannus results in demineralisation and cystic resorption of  underlying bone. 
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 3.Third stage-Deformity:
           During the healing process ,the extending granular pannus becomes fibrous 
uniting the two opposing  joint surfaces and causing a fibrous ankylosis and later on 
bony ankylosis.The muscles and soft tissues around the joint also undergo 
inflammatory changes in the collagen tissues and get atrophied.In addition, persistent 
inflammation causes weakening and even rupture of tendons. 
Ligaments are involved leading to joint subluxation or dislocation.Juxta –articular 
osteoporosis  occurs. 
Not all patients progress through all three stages.Some patients may have mild disease 
and recover,while others may suffer from chronic disease with crippling deformities. 
CHART NO. 3.3 : STAGES OF RA 
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 Clinical features: 
 Morning stiffness is very characteristics sign of rheumatoid arthritis.
 It usually involves small joints of the hands and feet and then symmetrically
affects the joints of wrists,elbows,ankles and knees.
 The proximal interphalangeal and metacarpo phalangeal joints are affected most
severely.
 It is a chronic disease with periodic acute  exacerbations and remissions.
 Bilateral symmetric polyarthritis is also a characteristic feature.
 There is joint line tenderness and the movements are painful and limited.
HISTOPATHOLOGY: 
  SYNOVIUM: 
      The synovium serves as an important source of nutrients for cartilage .Since 
cartilage itself is avascular. 
Synovial cells synthesise joint lubricates such as , 
      Hyaluronic acid 
      Collagens  
      Fibronectin 
1.Synovial lining or intimal layer-greatly hypertrophied 
2.Sub intimal area of synovium-the sub intimal area is heavily infiltered with 
inflammatory cells,including T and B lymphocytes,macrophages,mast cells, and 
mononuclear cells that differentiate into multinucleated osteoclasts. 
3.Cartilage:-In RA , type II collagen ,proteoglycans its integrity,resilience and water 
content all are impaired . 
4.Bone: Composed ,primarily of type I collagen ,bony destruction is a characteristics
of RA 
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 Hand and wrist deformity: 
       Rheumatoid nodules are particularly found in the subcutaneous tissue over the 
pressure points such as elbow hand ,occiput,sacrum .The centre of these nodules 
consists of an area of fibrinoid necrosis and cellular debris surrounded by radially 
dispersed palisade of local histiocytes. 
 Ulnar drift
 Intrinsic plus deformity
 Boutonniere or button hole deformity
 Swan neck deformity
 Elbow flexion deformity
 Z deformity or hitch
 Morrants bakers cyst
 Trigger finger
CHART NO. 3.4 :  DEFORMITIES OF RA 
REVIEW OF LITERATURE  2017
052
 CHART NO. 3.5 : PAIN AND SWELLING IN MCP JOINTS 
Ankle and toe’s deformity: 
 Atrophy of plantar metatarsal fat pad
 Achilles tendinitis
 Claw toes
 Calcaneal erosions
 Callosity under pressure
 Bunion
 Hallus valgus
 Hammer toes
 Plantar callosity
 Excessive plantar tilt of meta tarsals
 Flattening of longitudinal arch
 Prominent meta tarsal head
 Over riding of 2 and3 toes
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 CHART NO. 3.6 : DEFORMITIES OF RA   
Non specific inflammatory changes are seen in the blood vessels (acute 
vasculitis),lungs pleura ,pericardium ,myocardium, lymph nodes,peripheral nerves and 
eyes. 
The combination of bone deformity and swallon inflammatory tissue can prees on the 
spinal cord ,leading to ischeamia and widespread neurological consequences affecting 
all four limbs,bowel ,bladder function , or the respiratory muscles and centres in the 
brain stem that control respiration ,potentially resulting in death. 
IMMUNOPATHOGENESIS:  
CHART NO. 3.7 : IMMUNOPATHOGENESIS OF RA 
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 ONSET: 
    Insidious-70%,Oligoarticular-44%,polyarticular-35%,Palindromic-5% 
Insidious: 
RA  devolps insidiously over weeks or months with gradually increasing joint 
involvement. 
Polyarticular onset: 
The number of joints involved is highly variable but almost always the process 
is eventually polyarticular,involving five or more joints.Occasionally ,patients 
experience an explosive polyarticular onset occurring over 24-48 hours. 
Palindromic onset:  
Patients with RA persistant joint diseases, in which patients describe swelling 
in one or two joints that may last a few days to weeks then completely go away,later to 
return in the same or other joints ,with a pattern increasing over time.  
Joints which are affected are as follows : 
 Proximal interphalangeal joints -85%
 Meta carpo phalangeal joints -70%
 Wrists -70%
 Elbow -70%
 Knees -80%
 Ankles -65%
 Meta tarso phalangeal joints -30%
Non articular manifestations: 
 Pulmonary interstitial fibrosis -3%
 Episcleritis -1%
 Sjogren’s syndrome-2%
 Pleural effusion -1%
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 Extra articular manifestations: 
         Skin: 
 Palmar erythema
 Pyoderma gangrenosum
 Hyperhidrosis in extremities
 Raynaud’s phenomenon
 Painless non-tender sub cutaneous nodules
 Non healing ulcers in the fingers
 Vasculitis of nail beds and tip of the finger
Eyes: 
 Scleritis due to the granuloma formation
 Scleromalacia perforans
 Aneamia
 Cornea band keratopathy
          Ineffective production of erythropoiesis and the RBC is reduced due to the 
production of hemosiderin in the reticulo endothelial system. 
Respiratory system: 
 Recurrent pleural effusion
 Intersitial fibrosis
 Caplan’s syndrome
 Crico arytenoid arthritis is seen –dyspnoea,stridor.
 Pneumonia
 Pneumothorax
 Intersitial fibrosis
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 Cardio vascular system: 
 Pericarditis
 Aortic regurgitation and conduction defect.
 Myocardial infarction (due to coronary vasculitis)
 Endocarditis
Nervous system: 
 Symmetrical poly neuropathy
 Carpel tunnel syndrome
 Tarsal tunnel syndrome
 Wrist drop
 Foot drop
    Orthopaedics: 
 Juxta articular osteoporosis is seen
 Osteomalacia
 Sjogren’s syndrome: 
 Xerostomia
 Kerato conjunctivitis in association with connective tissue disorder.
   Felty ‘s syndrome: 
 Rheumatoid arthritis
 Spleenomegaly
 Leucopenia
  Gastrointestinal system: 
 Dysphagia
 Parotid enlargement
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 Muscles: 
 Myopathy(steroid,chloroquine)
 Tenosynovitis
 Weakness and atrophy
Rheumatoid vasculitis: 
 Mono neuritis multiplex
 Cutaneous ulceration
 Visceral infarction
Still’s disease: 
 RA is occuring  in children it is characterised by mono or 
polyarthritis,fever,maculopapular 
rash,hepatosplenomegaly,lymphadenopathy,leucocytosis.The joint deformity is rare 
but growth retardation is present. 
Diagnosis: 
     The essential criteria laid down by the American Rheumatism Association(ARA) 
for the diagnosis of RA are as follows; 
      1.Morning stiffness more than 1 hour 
     2.Arthritis of three or more joints areas observed by physician simultaneously ,have 
soft tissue swelling or joint effusion not just bony overgrowth. 
     3.Arthritis of hand joints: Wrists, metacarpo phalangeal joints, proximal 
interphalangeal joints. 
     4.Symmetric arthritis 
5.Rheumatoid nodules: Subcutaneous nodules over bony promimences,extensor
surfaces,or juxta articular surfaces observed by physician. 
    6.Serum rheumatoid factor demonstration  by any method for which the result has 
been positive in less than 5% of  normal control subjects. 
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 7.Radiographic changes : Typical changes of RA on posteroanterior  band and wrist 
radiographs which will show erosions or unequivocal bony decalcification localised in 
or most marked adjacent to the  involved joints. 
Differential Diagnosis: 
 Ankylosing spondylitis
 Systemic lupus erythematosus
 Reiter’s disease
 Osteoarthritis
 Gout and pseudo- gout
 Tuberculous arthritis
 Pyogenic arthritis
 Psoriatic arthritis
 Gonorrheal arthritis
 Haemophilic arthritis
Laboratory investigations: 
1.Complete blood count: 
 Aneamia
 Thrombocytosis
 Increased ESR
2.Increased acute phase proteins(CRP)
3.Increased plasma visciosity 
4.Serum protreins
 Decreased albumin
 Increased gammaglobulins
 Increased  IgG ,IgM,IgA
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 5. Serological tests:
             Rheumatoid factor-It is detected IgM  by, 
           A.Rose Waaler test- It is more specific and is said to be positive when more 
than 1:32  
        B.Latex test:It is sensitive and less specific and said to be positive when more 
than 1:20. 
6.Synovial fluid analysis: 
 Turbidity
 Reduced viscosity
 Increased  proteins
 Normal or decrease glucose concentration
 Increased polymorph count
7.Synovial biopsy and histological examination 
8.Arthroscopic examinations to evaluate damage to articular cartilage.
 9.Antinuclear antibodies is positive in 20 to 50% 
10.Antibodies to CCP(cyclic citrullinated polypeptide).This test has similar sensitivity 
and better specificity for RA. 
11.Radiological features  of RA 
Early: 
 Soft tissue swelling
 Periarticular osteopenia
 Periosteitis
 Erosions-periarticular and articular
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 Later: 
 Narrowed joint spaces is caused by loss of cartilage
 Juxta –articular erosion
 Articular surface irregularity
 Subluxation
 Large cystic erosions of bone
 Ankylosis
Ultrasound and MRI imaging has improved the sensitivity of detecting joint damage 
earlier in diseases. 
Ultrasound may detect  synovitis,effusions, and erosions, in addition to Doppler 
providing estimates of  ongoing inflammation. 
MRI  may show inflammatory synovitis that enhances with Gadolinium and shows 
early erosions 
Arthroscopy-   Synovium oedematous ,diffusely erythematous,and friable and later the 
synovium becomes thickened. 
Computerised tomography 
Scintigraphy. 
Renal biopsy-reduced tubular or  glomerular filteration rate 
Pulmonary biopsy-to distinguish rheumatoid nodules from carcinoma or to find out the 
diagnosis of fibrosing alveolitis. 
Management: 
          The treatment of this chronic crippling condition needs the team work of 
rheumatologist,ortho-paedic surgeon,physiotherapist,occupational therapist and social 
worker to provide compre-hensive management.The patient and his relatives must 
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 understand the condition fully and be well motivated to cooperate with the treatment 
which has to be prolonged. 
    The aim of the treatment is to 
 Relieve pain
 Keep the inflammatory process down to a minimum,
 Preserve joint motion
 Maintain the tone of muscles,
 Prevent deformities and stiffness of joint,
 Correct deformities
General treatment 
It is important to correct anaemia by haematinics and even blood transfusion 
may be neccessary.A nutritious diet with a high intake of vitamin c is very essential for 
these patients. 
Conservative Treatment 
The inflamed joint is kept at absolute rest by splinting the joint in the position 
of function.Physiotherapy is given during the acute phase. Active joint mobilisation and 
muscle strenthening exercise are also prescribed. 
Drug Therapy 
The drug used are as follows: 
1.Non-steroidal anti-inflammatory drugs 
2.Disease modifying anti rheumatoid drugs 
3.Steroids 
4.Cytotoxic drugs 
5.Newer drugs
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 Sugical Treatment: 
 The role of surgery is mainly reconstructive or rehabilitative.
 Synovectomy
 Osteotomy
Arthroplasty: 
Excision arthroplasty 
Replacement arthoplasty 
Foods that may worsen RA symptoms: 
        Red meat – contain high level of saturated fat and omega -6 fatty acids which can 
exacerbate inflammation. 
     Sugar and refined flour:Sugary snacks and drinks,white flour bread and pasta,white 
rice. 
     Fried foods and gluten, a protein found in grains such as wheat,rye,and barley and 
alchohol. 
REVIEW OF LITERATURE  2017
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REVIEW OF LITERATURE 
DRUG REVIEW-INTERNAL 
HYDRAGYRUM: 
Mercury is a heavy ,silver metallic element that exists as a liquid at room temperature. 
ATOMIC SYMBOL:  Hg 
ATOMIC NUMBER:80 
ATOMIC WEIGHT:200.592g/mol 
ODOR: Odorless 
BOILING POINT:657◦F 
MELTING POINT:-38◦F 
SOLUBILITY:Insoluble 
DENSITY:13.55 at 68◦F 
BLOCK-d-block 
➢ Mercury occurs in deposits throughout the world mostly as cinnabar(mercuric 
sulphide) 
➢ The red pigment vermilion is obtained by grinding natural cinnabar or 
synthetic mercuric sulphide. 
➢ Mercury does not react with most acids,such asdilute sulphuric acid,and it 
reacts with solid sulphur flakes,which are used in mercury spill kits to absorb 
mercury. 
Amalgams: 
➢ Mercury dissolves many other metals such as gold and silver to form 
amalgams. 
➢ Mercury readilycombines with aluminium to form a mercury-aluminium 
amalgam. 
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➢ Mercury can be absorped through the skin and mucous membranes and 
mercury vapors can be inhaled,so containers of mercury are securely sealed to 
avoid spills and evaporation. 
➢ The tobacco plant readily absorbs and accumulates heavy metals such as 
mercury from the surrounding soil into its leaves. 
Effects of mercury poisoning: 
Symptoms typically include sensory impairment,disturbed sensation and a lack of 
coordination 
இரசம் 
வேறுபெயர்: 
➢ சூரியவிரரோதி 
➢ பக்கிரம் 
➢ பதினெண்பந்தி 
➢ ஈசன் 
➢ விண்மருந்து 
➢ போரதம் 
➢ சிந்தூரம் 
பெய்கை:  
➢ வகீ்கமுருக்கி 
➢ உடல்ரதற்றி 
➢ உடல்உரமோக்கி 
➢ மலம்ரபோக்கி 
 
 
065
 
                                                                                                   REVIEW OF LITERATURE 2017 
 
 
பெொதுகுணம்: 
விழிர ோய் கிரந்தி குன்மம் னமய்ச்சூலல புண்குட் 
டழிகோலில் விந்துவிெோல் அத்லத-வழியோய் 
புரியு விதியோது புரியிரெோ னயல்லோம் 
இரியு விதியோது மில்லல.” 
SULPHUR: 
➢ Sulphur is a chemical element  with symbol of “S” and atomic number 16. 
➢ It is an abundant  multivalent  non –metal 
➢ Sulphur is the third most abundant mineral in the body about half concentrated 
in our muscles, skin, and bones and is essential for life. 
➢ It is widely distributed in close proximity to hot springs and volcanoes. 
➢ It is an essential nutrient and therefore cannot be synthesized by the human 
body and instead must be obtained from the diet. 
➢ Sulphur is not present as an isolated element in the body, the primary 
placement of sulphur in the human body is in the sulphur containing amino 
acids.(SSA) 
➢ Methionine , cysteine, and taurine  are  the sulphur containing amino acids. 
➢ The human body composed of 0.2-0.3%sulphur 
➢ Sulphur is the sixth most abundant macro-mineral in human breast milk. 
➢ Generally, proteins contain about 1%sulphur by weigh. 
Physical properties: 
Color: Pale yello ,non metallic 
Phase : Solid 
Crystalline structure &forms: Rhombic, Amorphous and prismatic 
Odour: Odourless 
Taste: Tasteless 
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Solubility: Insoluble in water 
Boiling point: 444.6 
Conductivity: A poor conductor of heat and electricity. 
Viscosity:Upon melting, sulphur is converted into a mobileYellow liquid  
Chemical properties 
Chemical formula:  S 
Compounds: Hydrogen sulphide,sodium sulphide 
Oxidation : Sulphur dioxide,sulphur trioxide 
Reactivity:It is a chemically reactive especially upon heating,sulphur reacts with 
meals. 
Bio chemical functions: 
➢ Cellular energy production&metabolism. 
➢ Maintainingblood glucose levels. 
➢ Protects nerve tissue-Synthesis neurotransmitters,improves memory 
➢ Antioxidant protection-scavenges or neutralizes free radicals and recycles 
oxidized Anti oxidants. 
Blood flow:  Produces both blood clotting factors as well as anti coagulants. 
Joint health: 
➢ Production of glycosamineglycan’s (  GAGS) 
➢ Chondroitin sulphate and hyaluronic acid 
Detoxification: By means of conjugation and chelation. 
Digestion: Production of hydrochloric acid 
Regulation of DNA replication and transcription 
Formation of skin hair and nails. 
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Proper immune response: 
Enhancing proliferation of lymphocytes,cytotoxic T cell and NK Cells. 
Supports healthy lipoprotein balance: Cholesterol,HDL,LDL 
Lungs: Protects against mucous formation in lungs. 
Eyes: Decrease cataract development. 
Dietary requirements and sources: 
          There is no specific dietary requirements for sulphur.Adequate intake of 
sulphur containing essential amino acid methioninewill meets the body needs. Food 
proteins rich in methionine and cystiene are the sources of sulphur. 
Metabolism of sulphur: 
➢ Sulphur is metabolised by all organisms,from bacteria plants and animals. 
➢ Sulphur is reduced or oxidized by organisms in a variety forms. 
➢ The elements is present in proteins, nucleic acid, sulfates, esters of 
polysacchrides, steroids, phenols,sulphur containing co- enzymes. 
Role of sulphur in Rheumatoid arthritis: 
➢ Sulfasalazine is a drug used in the treatment of rheumatoid arthritis and 
some other auto immune conditions. 
➢ It helps with pain and swelling and also slow the progression of arthritis over 
time. 
➢ Sulfasalazine is also known as a disease modifying anti rheumatic 
drug(DMARDs), because it not only decrease the pain and swelling of 
arthritis,but also prevent damage to joints. 
➢ It may reduce the risk of long term loss of function. 
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ைந்தைம்: 
➢ 64 போடோணங்களில் ஒன்று. 
வேறுபெயர்: 
➢ கோரிலழயின்  ோதம் 
➢ பலரவரீியம் 
➢ னசல்விவிந்து 
➢ ரதவியுரம் 
➢ னசந்தூரதோதி 
➢ சக்திபஜீம் 
➢ இரசசுரரோணிதம் 
➢ னபோன்வர்ெி 
➢ அதீதபிரோகசம் 
➢ பஜீம் 
ேகைைைள்: 
➢ பிறப்பு கந்தகம் 
➢ லவப்பு கந்தகம் 
➢ வோணனகந்தி 
➢ ரகோழிதலலனகந்தி 
சுகே: 
➢ லகப்பு 
➢ துவர்ப்பு 
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பெய்கை: 
➢ உடல்ரதற்றி 
➢ வியர்லவனபருக்கி 
➢ மலமிளக்கி 
➢ கிருமி சிெி 
➢ பித்தெரீ்னபருக்கி 
வெதம்: 
➢ னவண்லம- எல்லோ ர ோய்கலலயும் தீர்க்கும் 
➢ னபோன்லம-குற்றமற்றது.சூதகத்துடன் உறவோகி  ிற்பது 
➢ கிளிமூக்குச்சிவப்பு- வரலோகத்லத ஏமம்மோக்கும் 
➢ கோகம்- லரதிலர அற்றுரபோம். 
பெொதுகுணம்: 
ன ல்லிக்கோய்க் கந்திக்கு  ீள்பதினெண் குட்டமந்தம் 
வல்லலகவிலச குன்மம்வோயு கண்ரணோய்-னபோல்லோ 
விடகடிவன் ரமகர ோய் வறீுசுரம் ரபதி 
திடக் கிரகணகீபம் ரபோந்ரதர். 
ெிறப்பு: 
‘’னசந்தூரத் தெக்கோதி சிலல னகந்தி தோளகமும்’’ 
னசந்தூரம் னசய்வதற்குக் கந்தகம் உபரயோகம் ஆகும். 
 
 
070
 
                                                                                                   REVIEW OF LITERATURE 2017 
 
 
ZINC SULFATE(PAAL THUTHAM): 
It is an inorganic compound and dietery supplement. As a supplement it is used to 
treat zinc deficiency and to prevent the condition in those at high risk.The total 
content of zinc in an adult body is about 2g.PROSTATE GLAND is very rich in 
Zn(100mg|g). Zin is an intracellular element. 
IUPAC NAME: Zinc sulphate. 
Other names: White vitriol ,Goslarite 
Properties:      Chemical formula: ZnSo4 
Molar mass: 161.47g/mol(anhydrous) 
                      179.47 g/mol(monohydrate) 
                      287.53g/mol( hepatahydrate ) 
Appearance :   White powder 
Odour: Odourless 
Density:3.54g/cm 
Melting point: 680.c (1,256.F; 953 K ) Decomposes 
Boiling point: 740.c (1,360. F; 1,010 K) Decomposes. 
Solubility in water: 57.7g/100ml,(anhydrous 20.c) 
Solubility: Alcohols 
Refractive index (Nd):1.658 
Dietary Requirements: Adult: 10-15mg/day. 
It is increased in pregnancy and lactation.(by about 50%) 
Sources: 
  Meat, Fish, eggs, milk, beans & nuts,. 
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Biochemical functions: 
➢ Zinc sulphate is an essential component of several enzymes.(e.g)-
carbonic anhydrase, alkaline phosphatise, alchohol dehydrogenase, 
carboxy peptidase, super oxide dis mutase (SOD) 
➢ Zinc may be regarded as an antioxidant since the enzyme superoxide 
dismutase (Zn containing)protects the body against free radical damage. 
➢ The storage and secretion of insulin from the beta cells of pancreas 
require Zn. 
➢ Its plays a major role to maintain the normal levels of vitamin A in 
serum. 
➢ It promotes the synthesis of retinol binding protein. 
➢ It is required for wound healing.It enhances cell growth and division 
,besides stabilizing bio membranes. 
➢ GUSTEN, a Zinc containing protein of the saliva,it is important for taste 
sensation. 
SERUM Zn: 
➢ The concentration of Zn in serum is about 100mg/dl. 
➢ Erythrocytes contain higher content (1.5mg/dl)which is found in 
association with the enzyme carbonic anhydrase. 
Absorption: 
It is mainly absorped in the proximal jejunum and distal duodenum.Zn from 
the animal sources is better absorbed than the vegetables sources.Zn absorption 
appears to be dependent on a transport protein. 
Transport protein: 
Metallothionein 
 Its absorption is hampered by the presence of Phytate, calcium, copper and iron  
interfere while small peptides and amino acids promotes Zn absorption. 
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PATHOLOGIC CONDITIONS: 
➢ Zinc deficiency is associated with growth retardation ,poor wound healing, 
anaemia  loss of taste sensation, etc... 
➢ It may result in depression, dementia, and other psychiatric disorders   
MEDICINAL USES: 
➢ Zn is a divalent cation, is an essential micronutrient for humans and also plays 
an important role in maintaining immune status, and wound repair via 
regulation of DNA and RNA polymerases, thymidinekinase, and ribonuclease. 
➢ It maintains macrophage and neutrophil functions ,Natural Killer cells activity 
and complement activity. 
➢ It activates natural killer cells and phagocytic function of granulocytes and 
stabilize the plasma  subcellular membranes especially the LYSOSOMES. 
➢ It inhibits the expression of integrins by keratinocytes  and modulates the 
production of inflammatory mediators like nitric oxide. 
➢ While  about half of the total body Zn is in the bones,the skin contains nearly 
6%of total body Zn .As a movement of zinc across various tissues is limited 
and there is no storage depot ,the continuous external supply of zinc is 
important for metabolic needs, growth,and connective tissue repairing. 
➢ It also has anti inflammatory, immunomodulatory ,immunostimulatory 
activities. 
➢ It has also been demonstrated to decrease the serum levels of TNF-α and 
inhibit the TNF-α induced apoptosis of peripheral blood mononuclear  cells 
that helps in controlling the disease activity and reactional states. 
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ெொல்துத்தம் 
வேறுபெயர்: 
➢ னவள்லளத்துத்தம், 
➢ மடல்துத்தம், 
➢  ோகஉப்பு, 
➢ னவள்ளயீஉப்பு 
பெய்கை:  
➢ உடல்உரமோக்கி 
➢ துவர்ப்பி 
➢ இசிவகற்றி 
பெொதுகுணம்: 
முற்றிய குறிப்புண் முலறவிரண னசன்ெிதலெப் 
பற்றி ெின்றவோதம் படர்கரப்போன்-சுத்தவிழிக் 
கோசங் கணம்பில்லங் கண்ரணோய் குத்தந் னதோலலயும் 
வோசமிகு துத்தத்தோல் வோழ்த்து 
MIRABILIS JALAPA: 
      BOTANICAL NAME: Mirabilis jalapa 
      FAMILY NAME: Nyctaginaceae 
      SYNONYMS: Four o’clock flower , marvel of peru’ 
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MORPHOLOGY: 
It grows bushy, tender, perennial that can be grown from either a tuber or seeds. 
Leaves are opposite, slightly pointed oval leaves  and multi branching stems. 
 CHEMICAL CONSTITUENTS: 
Eight betaxanthins, Rotenoids (mirabijalone A,B,C and D,9-0-methyl -4-
hydroxyboeravinone B) can be isolated from the roots .Analysis of the methanolic 
extract of the aerial parts yields β-sitosterol, stigmasterol, ursolic acid ,oleanolic acid 
and brassicasterol 
  ACTIONS: Diuretic, Purgative, vulnerary (wound healing) purposes, anti arthritis 
MEDICINAL USES: 
➢ The leaves are used to reduce inflammation, pain and cures all types of joint 
diseases. 
➢ The root is believed an aphrodiasiac as well as diuretic and purgative. 
➢ A decoction of them (boiling and mashing) is used to treat abscess. 
➢ Leaf juice may used to  treat wounds. 
➢ The plant has a potential for bioremediation of soils polluted with moderate 
concentrations of heavy metals such as cadmium, mercury, lead etc..... 
➢ It is used in the treatment of anaemia and dropsy. 
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DRUG REVIEW 
2. EXTERNAL MEDICINE 
எருக்கு: 
BOTANICAL NAME: Calotrophisgigantea 
FAMILY NAME: Asclepiadaceae. 
SYNONYMS: அருக்கன் 
MORPHOLOGY: 
It is a large erect shrub grows upto 4m in height .Leaves are exstipulate, simple and 
opposite decussate. Horn like appendages towards the outside known as staminal corona. 
CHEMICALCONSTITUENTS:       
            Calotropin, calotoxin, calactin, gigantin, giganteol & uscharin. 
ACTIONS: Alterative, Analgesic, Laxative stimulant. 
ப ொதுகுணம்: 
எலிவிடங் குட்டமைய மைறு கிருைி 
வலிசூமல வாயுவிட ைந்தம்-ைலபந்தம் 
எல்லாைகலு மைருக்கிமலமயக் கண்டால் 
வில்லார் நுதமல! விளம்பு. 
 
 
 
076
 
                                                                                                REVIEW OF LITERATURE 2017 
 
 
 
MEDICINAL USES: 
The leaves of C.gigantiaare used for the treatment of poisonous snake bites, periodic 
fever. 
 
Latex of this plant is used to cure dental problems, rat bite swelling, gonococcal arthritis, 
and rheumatoid arthritis. 
 
The latex is applied to soften the outer skin portion while removing thorns, it is 
commonly used on fresh cuts to stop bleeding and have been used as anti-inflammatory 
agent in folk medicine. 
 
The siddha physician considers this plant as vegetable mercury. Flora buds or petals are 
medicinally used in asthma. 
சதுரக்கள்ளிஇலை: 
BOTANICAL NAME: Euphorbia antiquorom 
FAMILY NAME: Euphorbiaceae 
SYNONYMS: திருவாற்கள்ளி 
MORPHOLOGY: 
It is largest armed tree with cactus like in appearence 5-7cm thick,green glabrous 
branching from upper parts, The odour of its latex is pungent and irritating. 
CHEMICAL CONSTITUENTS: 
Glutinol, stigmasterol, taraxerol, tri-o-methlellagic acid, friedelanol, trimethoxylcoumarin, 
antiquarian,antiqual A and B, Sitosterol 
ACTIONS: Antiarthritic, Anti inflammatory, Anodyne, stomachic, purgative &emetic 
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ப ொதுகுணம்: 
“வாத முடக்கலும்வங்கிரந்தி குட்டம்மபாஞ் 
சீதமைாழி யுங்கிருைி மசருமைா-ைாமத! 
பருபக்க  ம ாயுடமே பாழ்ங்கரப்பான்றரீுந் 
திருகுக்கள்ளிப் பாலாற் மரளி 
MEDICINAL USES: 
Euphorbia antiquoromis traditionally used in inflammatory disorders such as 
Rheumatism, and Gout, to relieve pain in rheumatism and toothache, in nervine diseases. 
The juice is acrid, anti-inflammatory, deobstruent, purgative and useful in dropsy, 
neuropathy, deafness, cough and cutaneous disease. The milk of E. antiquorom reduced 
joint swelling. It also induce diarrhea.  
 ிரண்லை: 
BOTANICAL NAME: Cissus quandrangularis 
FAMILY NAME: Vitaceae 
SYNONYMS: வஜ்ஜிரவல்லி,BONE SETTER, devil, S backbone adament creeper 
MORPHOLOGY: 
It is perennial plant of the grape family.it reaches 1.5mheight and has quadrangular 
sectioned branches with internodes 8-10 cm long. It is low growing shrub four sided stem, 
climbing plant. numerous tendrils grow out of the plants nodes. 
CHEMICAL CONSTITUENT: 
Two isomeric ketosteroids, quercetin, resveratrol, friedelin β-sitosterol,  
 
078
 
                                                                                                REVIEW OF LITERATURE 2017 
 
 
ACTIONS: 
Alterative, stomachic, anti-rheumatism, anti oxidant, analgesic, Antiulcer and 
antihaemorrhoids 
ப ொதுகுணம்: 
பிரண்மடமயய் யால்வறுத்துப் பின்ேமரத் துைாமத 
மவருண்டிடா மதற்றுவிழுங்கில்–அரண்டுவரும். 
மூலத் திேவடங்கும் மூலவி ரத்தைறும் 
ஞாலத் தினுள்மள  வில். 
MEDICINAL USES: 
It is a traditional medicine for joint and bone health as well asvarious feminine disorders 
and bone growth rates.It increasing bone mass and accelerating fracture healing rates 
which gives it the traditional name BONESETTER. 
Cissus may have muscle relaxing properties. It extracts standardized to2.5%ketosteroids 
has shown biological activity in humans. 
Oral intake doses suggesting an enhancement of GABAa signaling.There appears to be a 
concentration dependent increase in the secretion of insulin-like growth factors in 
osteoblasts at aconcentration range feasible to occur following oral ingestion. 
Collagen synthesis has been noted to be increased in osteoblasts. It can promote the 
proliferation and differentiation and may influence the promotion of mesenchymal stem 
cells into osteoblasts. 
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 ற் ைொகம்: 
BOTANICAL NAME: Mollugocerviana 
FAMILY NAME: Molluginaceae 
SYNONYMS: சீதம்,பற்பாடம்,Threadstem carpetweed. 
MORPHOLOGY: 
It is an annual herb producing a thin, erect stem upto about 20cm tall with slender, 
cylindrical stems, branches umbellate the  nodes are thickened. The seeds are numerous 
smooth,yellowish brown,without tubercular points. The narrow, waxy leaves are 
upto1.5cm long, linear in shape arranged in whorls around the stem. 
CHEMICAL CONSTITUENTS: Flavone-c-gycoside, orientin,  and vitexin 
ACTIONS: Antiseptic,febrifuge,diaphoretic,anti-rheumatism,antiseptic,aperient. 
மபாதுகுணம்: 
சீதவாதச் சுரமுந்தீராத தாகமும் மபாம் 
மபாதவிரு கண்குளிரும் மபாய்யலமவ-பூதலத்துள் 
வற்பார் பயித்தியமுைாபித்த முந்மதாமலயும் 
பற்பாடகத்மத யுன்ேிப் (பார்) 
MEDICINAL USES: 
  It is an effective herb used in reduced fever (flowers and tender shoots) stimulating the 
gastric juices(plant)to cures gastritis, diarrhoea, excessive thrist etc.. gout and 
rheumatism(root).An infusion of the plant promoteslochial discharge and is considered a 
cure for gonorrhea.The root is mixed with gingely oil and it is boiled to apply over the 
affected area to reducing the pain and swelling,and very effective for all arthritic diseases. 
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பெருகன்கிழங்கு: 
BOTANICAL NAME: Alocasiaindica 
FAMILY NAME: Araceae 
SYNONYMS: உலக்மக,கந்தபுட்பி,முசுலம் 
MORPHOLOGY: 
Alocasia is a genus of broad –leaved rhizomatous or tuberous perennials from the family 
of araceae.The large cordate or sagittate leaves grow to length of 20-90cm on long 
petioles.The stem(a corm)is edible, but contains raphide crystals of calcium oxalate along 
with other irritants(possibly a protease) 
CHEMICAL CONSTITUENTS: 
A Mixture of triglochinin and isotriglochinin and hydrolyzing enzymes.The plant also 
contains a flavones and a saponin and petioles contain up to 0.018%of HCN.A 
Glycoprotein lectin, hemaagglutinin,is present in the rhizome. It also contains 
glucose,fructose, a phytosterol-like compound and an alkaloid.The tubers and roots have 
high contents of soluble oxalates in the form of acicular crystal. 
ACTIONS: Anti-vadha, febrifuge and deobstruent 
ப ொதுகுணம்: 
மைருகன்கிழங் கதுதான் மைகத்மதப் மபாக்கும் 
துருவுகுன்ை மூலந்துமடக்கும் –மபருைீேள 
அத்திசுரம் ஐயறுக்கும் அங்கம் குளிர்விக்கும் 
அத்திமுமலைாமத அறி. 
 
081
 
                                                                                                REVIEW OF LITERATURE 2017 
 
 
MEDICINAL USES: 
It is used in inflammation, and the rootstock is cooling, mild laxative and diuretic, useful 
in piles, habitual constipation, inflammation, rheumatism, leprosy, anasarca, jaundice, 
diseases of spleen. 
The ash of the rootstocks mixed with honey is used in cases of aphthae.The leaf juice is 
astringent. Merugulli oil is intake of daily morning before to known the stamina and take 
internally it will effective for RHEUMATOID ARTHRITIS, osteoarthritis, gonococcal 
arthritis and swelling and chronic ulcers are cured. 
நேர்வொளம்: 
BOTANICAL NAME: Croton tiglium 
FAMILY NAME: Euphorbiaceae 
SYNONYMS: வாளம்,மசாபி, ாகணம் 
MORPHOLOGY: 
It is evergreen tree having a height of 15-20 feet. Leaves are 2 to 4 inch in length, shiny 
and smooth to touch, ovate in shape and are dentates. It is monoceous. Seeds are ovate in 
shape bearing brown colour. These are 1/2 to 2/3 inch in length and are very similar to  
that of riccinus sativa seeds. Pulps of the seeds is reddish brown in color with sticky 
appearance. 
CHEMICAL CONSTITUENTS: Crotonosides, croton oil glycosides and Toxoalbumin 
ACTIONS: Purgative, rubefacient, cathartic anthelmintic and stimulant 
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ப ொதுகுணம்: 
எந்தவியாதி யிேங்கமளயும் சாடிைல 
பந்தவிேேமயப் பரிபரித்து –வந்தமவப்மப 
பாபிமயே ைாட்டுதலால் பாடாண மவம்மையினும் 
மசாபி ைகமசாபிமயன்று மசால்.  
MEDICINAL USES: 
It is very helpful in chronic constipation and indigestion related problems. It improves 
circulation in the body.It is also a good  anti-inflammatory agent.It is uses in poisoning 
cases.It is also applied on the scalp as it is helpful in re-growth of hairs.Its oil is used in 
eyes related problems. 
நசரொங்பகொட்லை: 
BOTANICAL NAME: Semecarpusanacardium 
FAMILY NAME: Anacardiaceae 
SYNONYMS: வல்லாதி, எரிமுகி,  ந்திவித்து, Marking nut ,ballataka 
MORPHOLOGY: 
Medium sized trees with rough dark, brown bark. Leaves are simple, obovate-oblong, 
cordate at base. Drupe globose,black 
CHEMICAL CONSTITUENTS: 
semecarpel, catechol, cardol, anacardal, anacardic acid, Nuts contains 
biflavonesbinaringenin, tetrahydrobutafavone, nut shell contain biflavonone 
semecarpuflavanone, semecapetin, kernel contains semidrying oil & glycosides 
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ACTIONS: 
 Alterative, anti-vadha, caustic, Anti inflammatory, Anti -carcinogenic 
ப ொதுகுணம்: 
குட்டங்கயமராகங்மகால்லும்விடபாகந் 
துட்டந்தருகிருைிசூமலயும்மபாம்-ைட்டலருங் 
கூந்தன்ையிமலகிரந்திக்கூட்டம்மபாமசங்மகயில் 
ஏந்துமசங்மகாட்மடதேேமய. 
MEDICINAL USES: 
Fruit used in ascitis, rheumatism, asthma, neuralgia,epilepsy and psoriasis and also warts 
and tumors .It has antiatherogenic activity. It shows such antioxidant property and it has 
capacity to scavenge the superoxide and hydroxyl radicals at low conc.The nuts extracts 
showing significant anti inflammatory activity for both immunological and non 
immunological origin and inhibit the proinflammatorycytokienes production. 
ஏள்: 
BOTANICAL NAME: SESSAMUM INDICUM 
FAMILY NAME: Pedaliaceae 
SYNONYMS: திலம் 
MORPHOLOGY: 
It is an annual plant growing 50-100cm tall with opposite leaves 4-14cm.Typically the 
seeds are about 3-4mmlong by 2mm wide and 1mm thick.The seeds are ovate,slightly 
flattened. 
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CHEMICAL CONSTITUENTS: 
It contains lignanssesamolin, sesamin, pinoresinol and lariciresinol Oleic acid and 
palmitic acid 
ACTIONS: Demulcent,emollient , Nutritive and Tonic. 
ப ொதுகுணம்: 
எள்ளுைருந்மதக்மகடுக்கும்எறேலாந்திண்மைதரும் 
உள்ளிமலமயச்மசர்க்கும்உதிரத்மதத் –தள்ளூைிரு 
கண்ணூக்மகாளிமகாடுக்குங்காசமுண்டாம்பித்தமுைாம் 
பண்ணூக்கிடர்புரியும்பார். 
MEDICINAL USES: 
Sesame oil has been used in various disorders for anxiety, nerve and bone disorders, poor 
circulation, lowered immunity and bowel and skin problems. 
Sesame seeds may improve the condition of patients with rheumatoid arthritis 
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MATERIALS AND METHODS 
SELECTION OF DRUGS: 
  I have selected  the trial drug “RASA CHENDHURAM”(Int)for this study from 
classical siddha literature “Sigicharathnadeepam” and Roga sanjeevi thylam(Ext) 
from, “ Therayar thylavarga surukkam” 
The raw drugs were purchased from the raw drug shop R.N. Rajan&co paris.After 
proper authentication by the pharmacognist,siddha central research was made. 
        4.1 Before Purification       4.2 Brick with turmeric powder 
Grinding and purification
             4.3 squeezing method              4.4 After purification 
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Purification of  Mercury: 
Mercury is grinded along with brick powder and turmeric powder each for about one 
hour and  is washed with pure water and mixed with the juice of  Acalyphaindica and 
ignited well until it detoxify 
     4.5 Before purification   4.6 Melting sulphur 
4.7 Gandhagam poured into milk        4.8 After Purification        
Purification of sulphur: 
     Sulphur is placed in an iron spoon(the iron spoon is lined with cow’s butter and the 
spoon is heated till the sulphur melts,thismixure is immersed in inclined position  in 
cow’s milk.This procedure is repeated for 30 times to get purified sulphur.Each time 
,fresh milk is to be used 
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     4.9 Before purification        4.10 After purification        
Purification of sulphate of zinc: 
70 gm of sulphate of zinc is dissolved in 70ml of viniger(old rice fermented water )for 
3days and isolated . 
4.11 Mirabilis jalapa-yellow variety juice               4.12 Ignited chendhuram  
         4.13 Grinding chendhuram       4.14 Grinding chendhuram 
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4.15 End product of Chendhuram 
PREPARATION OF THE INTERNAL DRUG RASA CHENDHURAM 
INGREDIENTS: 
P.Rasam (Mercury) - 70gm  
P.Gandhagam (Sulphur)             -70gm 
P.Paalthutham (Sulphate of zinc) - 70gm    
Mirabilis jalapa-Q.S 
 The flower juice of the yellow variety of Mirabilis jalapa is to be grinded well
with the above mentioned raw drugs in the stone mortar for 6 hours(2 saamam) 
till the juice and the drugs gets spreaded well in the mortar on all sides.Then it 
is to be collected using the spatula without any wastage. Next the collected 
medicine is to be placed in a mud jar and is closed with a proper lid and sealed 
up tightly with 7 layers of mud pasted cloth.After the sealing is dried, the mud 
jar is placed in the vaalugaendiram.Then it is to be ignited with kamalakini for 
6 hours (2 saamam) then for kaadakini for next 6 hours. Then it is to be left 
aside for the whole night to allow it to cool. Then the settled medicine is to be 
collected safely and placed in the mortar for grinding to get a fine chendhuram. 
Then it is to be collected and placed in a air tight container. 
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DOSAGE : 122-244 mg (twice daily) 
ADJUVENT  : Honey 
INDICATION :  All types of fever, 80 types of vadham. 
DURATION: 48 days(1 mandalam) 
EXTERNAL MEDICINE: 
ROGA SANJEEVI THYLAM: 
Earukkuilai(Calotropisgigantea)  :175gm 
Kattusathurakalli  (Euphorpiaantiquorum) :175gm 
Pirandai(Cissusquadrangularis)         :175gm
Parpadagam (Mollungacerviana)  :175gm
Merugankizhangu(Alocasiaindica)  :175gm 
Serangkottai(Semecarpusanacardium)  :175gm 
Purified valaparupu(Croton tiglium)   :17.5gm 
 Goat milk :1575gm 
Gingellyoil(sesamumindicum) :350gm 
4.16 CALOTROPHIS GIGANTEA            4.17 EUPHORPIA ANTIQUORUM 
MATERIALS AND METHODS  │2017
090
4.18 CISSUS QUADRANGULARIS                4.19 MOLLUNGA CERVIANA 
         4.20 ALOCASIA INDICA                 4.21 SEMECARPUS ANACARDIUM 
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         4.22 CROTON TIGLIUM          4.23 RAW DRUGS DECOCTION 
4.24 DECOCTION MIX WITH OIL            4.25 THEN MIX THE JUICE 
          4.26 And mix the goat milk       4.27 Roga Sanjeevi Thylam
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PREPARATION: 
 The juice and latex of calotropisgigantea and euphorbia antiquorum and the
juice of cissusquadrangularis ,Hedyotiscorymbosadecoction,and the decoction
Alocasiaindicaeach are collected in the equal ratio palam 5(175gm).Then
gingelly oil of palam 10(350gm) and goats milk  palam45(1575gm) are mixed
together with the above mentioned juices .And the cut pieces of
semecarpusanacardium and the  purified croton tiglium are mixed together
with the above oil .And heated to deepakini until it attains its consistency then
the end product is filtered and to be collected.
INDICATIONS: 
Vadharogam, Swasarogam, Magaavadharogam 
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EXTERNAL THERAPHY   
External theraphies in siddha system are broadly classified under 32 categories.External 
theraphies  are assuming great importance ,since they are safe and efficient though being 
drugless.Theraphies are aimed at maintain a healthy balance of the three humours,  and 
nourishment of the sapta thathus   
 OTTRADAM -FOMENTATION 
Fomentation is a type of heat external theraphy is applied to the skin to release swelling or pain
so as to alleviate the deranged vadha disease by bringing in fresh energy by improving
cutaneous circulation and neural conductivity. 
Ottradam or fomentation: 
            The substances like lime powder,bran,brick powder,egg-shell,leaves of medicinal 
plants like nochi(vitex negundo),erukku(calotrophis gigantea),amanakku(Riccinus communis)
etc are tied  in a cloth as a bundle.This medicated bundle is heated and applied over the affected
area. 
Ottradam is given to the patients with the complaints of contusion and other swelling it is also 
used in certain dermatological  conditions. 
Ottradam is the application of hot or cold packs of substances like medicinal
leaves,pulses,cereals,rice and wheat husk, etc…,on or around the affected part,this warm 
application induces fomentation ,or sweating which helps to disperse aggrevated doshams in
the affected area and dilating all body channels for cleansing. 
This type of treatment is very effective for vatham ailments(Arthritis) and painful conditions
like muscle cramps ,bone disorders etc… 
 PROCEDURE: 
Roga sanjeevi thylam is to be applied first over the affected area. 
Then the husk of the wheat is to be tied as a  bundle,i.e(kizhi). 
The kizhi is heated by placing on the heated pan. 
Then the heated kizhi is used to give ottradam. 
Repeat the same for 7 more times. 
While giving Ottradam theraphy to my patients I observed that,there is remarkable  reduction 
of pain ,swelling, and morning stiffness since my medicated oil (Roga sanjeevi thylam), 
contain anti-vatha property herbs.Comparing group I  and group II subjects  the patients who 
are all comes under  group II had good improvement than group I 
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STANDARDIZATION PARAMETERS: 
Traditional way of testing chendhuram: 
Colour: 
Dark red in colour without any shiny appearance 
Taste and odour:  
Tasteless and odourless  
Luster: 
Did not regain luster on heating again at same temperature 
Floating on water: 
Sample floats on water. Did not immediately immersed in water 
Finger furrows test:  
Impinged in the papillary ridges when the sample rubbed in between index finger 
and thumb 
PHYSICOCHEMICAL ANALYSIS 
Determination of Moisture Content (Loss on drying) 
Procedure set forth here determines the amount of volatile matter (i.e. Water drying off 
from the drug). For substances appearing to contain water as the only volatile 
constituent, the procedure given below, is appropriately used.  
Place about 10 g of drug (without preliminary drying) after accurately weighing 
(accurately weighed to within 0.01 g) it in a tarred evaporating dish. For example, for 
underground or unpowered drug, prepare about 10 g of the sample by cutting shredding 
so that parts are about 3 mm in thickness. 
Seeds and fruits, smaller than 3mm should be cracked. Avoid the use of high speed 
mills in preparing samples, and exercise care that no appreciable amount of moisture is 
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lost during preparation and that the portion taken is representative of the official sample. 
After placing the above said amount of the drug in the tarred evaporating dish dry at 
105o for 5 hours, and weigh. Continue the drying and weighing at one hour interval 
until difference between two successive weighing corresponds to not more than 0.25 
%. Constant weight is reached when two consecutive weighing after drying for 30 
minutes desiccator, show not more than 0.01 g difference.  
Determination of Total Ash 
Incinerate about 2 to 3 g accurately weighed, of the ground drug in a tarred platinum or 
silica dish at a temperature not exceeding 450o until free from carbon, cool and weigh. 
If a carbon free ash cannot be obtained in this way, exhaust the charred mass with hot 
water, collect the residue on an ash less filter paper, incinerate the residue and filter 
paper, add the filtrate, evaporate to dryness, and ignite at a temperature not exceeding 
450o. Calculate the percentage of ash with reference to the air-dried drug.  
Determination of Water Soluble Ash 
Boil the ash for 5 minutes with 25 ml of water, collect insoluble matter in a Gooch 
crucible or on an ash less filter paper, wash with hot water, and ignite for 15 minutes at 
a temperature not exceeding 450o. Subtract the weight of the insoluble matter from the 
weight of the ash; the difference in weight represents the water-soluble ash. Calculate 
the percentage of water-soluble ash with reference to the air-dried drug. 
Determination of Acid Insoluble Ash  
Boil the ash obtained in total ash for 5 minutes with 25 ml of dilute hydrochloric acid, 
collect the insoluble matter in a Gooch crucible or on an ash less filter paper, wash with 
hot water and ignite to constant weight. Calculate the percentage of acid-insoluble ash 
with reference to the air dried drug. 
Determination of pH Values 
The pH value of an aqueous liquid may be defined as the common logarithm of the 
reciprocal of the hydrogen ion concentration expressed in g, per liter. Although this 
definition provides a useful practical means for the quantitative indication of the acidity 
or alkalinity of a solution, it is less satisfactory from a strictly theoretical point of view. 
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No definition of pH as a measurable quantity can have a simple meaning, which is also 
fundamental and exact.  
The pH value of liquid is determined potentiometric ally by means of the glass, 
electrode and a suitable pH meter.  
METHOD  
Operate the PH meter and electrode system to the manufacturer’s instruction. 
Standardize the meter and electrodes with 0.05 M potassium hydrogen phthalate (pH 
4.00) when measuring an acid solution, or with 0.05 M sodium borate when measuring 
an alkaline solution. At the end of a set of measurement, take a reading of the solution 
used to standardize the meter and electrodes. The reading should not differ by more 
than 0.02 from the original value at which the apparatus was standardized. If the 
difference is greater than 0.05, the set of measurements must be repeated. The pH/ 
e.m.f. relationship of the particular glass electrode in use must be checked. The 
PH/follows; standardize with 0.05 M sodium borate. When the reading is higher by 
0.02 or more, or over by 0.05 or more then the appropriate value in the Table, correct 
the PH values of all solutions measured on that day, assuming the e.m.fog the glass 
electrode cell to be linearly related to the PH value of the solution which it contains. 
Unless otherwise stated all solution must be brought to laboratory temperature prior to 
measurement. Whilst the PH/temperature coefficient of 0.5 M potassium hydrogen 
phthalate may be neglected that of 0.05 M sodium borate must be taken into account in 
accordance with the value given in the table. When measuring PH values above 10.0 
make sure that the glass electrode is suitable for use at the alkaline and of the PH scale 
and apply any correction that is necessary 
Solutions from PH 4.0 to 6.2 are prepared by mixing 50 ml of 0.2 M boric acid-
potassium chloride with the quantities of 0.2 N sodium hydroxide, specified in the 
following table, and diluting with freshly boiled and cooled water to produce 200 ml; 
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S.NO  
1  4.0 0.40  
2  4.2 3.70  
3  4.4 7.50  
4  4.6 12.15  
5  4.7 17.70  
6  4.9 20.35  
7  5.0 23.85  
8  5.1 29.95  
9  5.2 26.95  
10  5.3 35.45  
11  5.4 26.45  
12  5.6 39.95  
13  5.8 43.00  
14  6.0 45.45  
15  6.2 47.00  
Physico chemical analysis of RASA CHENDHURAM: 
      Table-1- Physico chemical analysis of RCM: 
Name of the Experiment Value 
Loss on Drying (at 105◦ C) 0 % 
   Total ash 100 % 
   Water Soluble Ash 24.5 % 
   Acid Insoluble Ash 55.11 % 
   pH Value (10%) 3.07 % 
pH  
ml of 0.2 N 
sodium 
hydroxide 
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HEAVY METAL ANALYSIS : 
Table - 2-Heavy metal analysis of RCM 
Heavy metal Procedure Observations 
Mercury  1. Add 5ml of hydrochloric
acid  to little substance,
precipitate appears
2. Then boil the precipitate
with water. It does not
dissolves add sodium
hydroxide solution . heat
it and filter
No Black precipitaion 
appears. 
Lead  1.add 2ml of potassium chormate
to salt solution.  
No yellow precipitate 
appears. 
Arsenic  To 10 drops of solution. Add 6ml 
NH3 untilneutral.make the 
solution acidic b adding one or 
more drops of 6 M HCL. Add 1 
ml of thioacetamide and stir well. 
Heat the test tube in the boiling 
water bath for 5 minutes  
No red orange precipitate  
Or 
No Yellow or brown 
precipitates appears. 
Cadmium  Add 2ml of solution, add 1 ml 
NaOH, add  1ml of distal water 
and add  1 ml of Hcl 
No Yellow  precipitates 
appears.
Chromium  To 10 drops of solution, add 1ml 
of 3% H2O2 then add 6M NaOH 
dropwise untill the solution is 
basic. Heat in a boiling water 
bath for a few minutes 
No  yellow solution of 
CrO42 form. 
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TOXICOLOGICAL STUDY: 
ACUTE ORAL TOXICITY STUDY OF RASA CHENDHURAM 
(OECD GUIDELINE – 423) 
Introduction: 
 The acute toxic class method is a stepwise procedure with the use of 3 animals
of a single sex per step.
 Depending on the mortality and/or the moribund status of the animals, on
average 2-4 steps may be necessary to allow judgement on the acute toxicity of
the test substance.
 This procedure is reproducible, uses very few animals and is able to rank
substances in a similar manner to the other acute toxicity testing methods.
 The acute toxic class method is based on biometric evaluations with fixed doses,
adequately separated to enable a substance to be ranked for classification
purposes and hazard assessment.
 In principle, the method is not intended to allow the calculation of a precise
LD50, but does allow for the determination of defined exposure ranges where
lethality is expected since death of a proportion of the animals is still the major
endpoint of this test.
 The method allows for the determination of an LD50 value only when at least
two doses result in mortality higher than 0% and lower than 100%.
 The use of a selection of pre-defined doses, regardless of test substance, with
classification explicitly tied to number of animals observed in different states
improves the opportunity for laboratory to laboratory reporting consistency and
repeatability.
Principle of the Test: 
It is the principle of the test that based on a stepwise procedure with the use of 
a minimum number of animals per step, sufficient information is obtained on the acute 
toxicity of the test substance to enable its classification. The substance is administered 
orally to a group of experimental animals at one of the defined doses. The substance is 
tested using a stepwise procedure, each step using three animals of a single sex. 
Absence or presence of compound-related mortality of the animals dosed at one step 
will determine the next step, i.e. 
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− no further testing is needed 
− dosing of three additional animals, with the same dose  
− dosing of three additional animals at the next higher or the next lower dose 
level. The method will enable a judgment with respect to classifying the test substance 
to one of a series of toxicity classes. 
Methodology: 
Selection of Animal Species 
The preferred rodent species is thewistar albino rat, although other rodent 
species may be used. Healthy young adult animals are commonly used laboratory 
strains should be employed. Females should be nulliparous and non-pregnant. Each 
animal, at the commencement of its dosing, should be between 6 to 8 weeks old and the 
weight (150-200gm) should fall in an interval within±20 % of the mean weight of any 
previously dosed animals.  
Housing and Feeding Conditions 
The temperature in the experimental animal room should be 22ºC + 3ºC. 
Although the relative humidity should be at least 30% and preferably not exceed 70% 
other than during room cleaning the aim should be 50-60%. Lighting should be 
artificial, the sequence being 12 hours light, 12 hours dark. For feeding, conventional 
laboratory diets may be used with an unlimited supply of drinking water. Animals may 
be group-caged by dose, but the number of animals per cage must not interfere with 
clear observations of each animals. 
Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, and kept 
in their cages for at least 7 days prior to dosing to allow for acclimatization to the 
laboratory conditions 
Test Animals and Test Conditions:  
Sexually mature Female Wistar albino rats (150-200gm) were obtained 
fromTANUVAS,Madhavaram, Chennai.All the animals were kept under standard 
environmental condition (22±3°C).  The animals had free access to water and standard 
pellet diet (Sai meera foods, Bangalore). 
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Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, and kept 
in their cages for at least 7 days prior to dosing to allow for acclimatization to the 
laboratory conditions 
Preparation for Acute Toxicity Studies 
 Rats were deprived of food overnight (but not water 16-18 h) prior to administration 
of the, RASA CHENDHURAM. 
The principles of laboratory animal care were followed and the Institutional 
Animal Ethical Committee approved the use of the animals and the study design 
IAEC approved number –IAEC/XL VIII 29/CLBMCP/2016 
Test Substance : RASA CHENDHURAM 
Animal Source : TANUVAS,Madhavaram, Chennai.  
Animals : Wister Albino Rats (Female-3+3) 
Age  : 6-8 weeks 
Body Weight on Day 0 : 150-200gm. 
Acclimatization : Seven days prior to dosing. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number and individual   
   marking by using Picric acid. 
Numberofanimals                 : 3 Female/group,  
Route of administration     :   Oral  
Diet  : Pellet feed supplied by Sai meera foods Pvt Ltd, 
Bangalore 
Water  : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages 
   provided with bedding of husk. 
Housing temperature :  between 22ºC +3ºC.   
Relative humidity  :  between 30% and 70%, 
Air changes   : 10 to 15 per hour and  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 14 Days 
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Administration of Doses:  
RASA CHENDHURAM was suspended in prescribed medium and 
administered to the groups of wister albino rats in a single oral dose by gavage using a 
feeding needle. The control group received an equal volume of the vehicle. Animals 
were fasted 12 hours prior to dosing. Following the period of fasting, the animals were 
weighed and then the test substance was administered. Three Female animals are used 
for each group. The dose level of 5 mg/kg body weight was administered stepwise. 
After the substance has been administered, food was withheld for a further 3-4 hours. 
The principle of laboratory animal care was followed. Observations were made and 
recorded systematically and continuously as per the guideline after substance 
administration. The visual observations included skin changes, mobility, aggressively, 
sensitivity to sound and pain, as well as respiratory movements. Finally, the number of 
survivors was noted after 24 hrs and these animals were then monitored for a further 14 
days and observations made daily. The toxicological effect was assessed on the basis 
of mortality. 
Observations:  
Animals are observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the 
first 4 hours, and daily thereafter, for a total of 14 days, except where they need to be 
removed from the study and humanely killed for animal welfare reasons or are found 
dead. It should be determined by the toxic reactions, time of onset and length of 
recovery period, and may thus be extended when considered necessary. The times at 
which signs of toxicity appear and disappear are important, especially if there is a 
tendency for toxic signs to be delayed. All observations are systematically recorded 
with individual records being maintained for each animal. 
Observations include changes in skin and fur, eyes and mucous membranes, and 
also respiratory, circulatory, autonomic and central nervous systems, and somatomotor 
activity and behavior pattern. Attention was directed to observations of tremors, 
convulsions, salivation, diarrhoea, lethargy, sleep and coma. The principles and criteria 
summarized in the Humane Endpoints Guidance Document taken into consideration. 
Animals found in a moribund condition and animals showing severe pain or enduring 
signs of severe distress was humanly killed. When animals are killed for human reasons 
or found dead, the time of death was recorded. 
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REPEATED DOSE 28-DAY ORAL TOXICITY (407) STUDY OF 
RASA CHENDHURAM 
 
Test Substance  : RASA CHENDHURAM 
Animal Source  : TANUVAS,Madhavaram, Chennai.   
Animals   : Wister Albino Rats (Male -24, and Female-24) 
Age    : 6-8 weeks 
Body Weight               : 150-300gm. 
Acclimatization  : Seven days prior to dose. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number   and    individual  
   marking by using    Picric acid 
Diet    : Pellet feed supplied by Sai meera foods Pvt Ltd,         
                 Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages    
                 provided with bedding of husk. 
Housing temperature :  between 22ºC + 3ºC.    
Relative humidity  :  between 30% and 70%, 
Air changes    : 10 to 15 per hour  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 28 Days. 
 
Methodology 
Randomization, Numbering and Grouping of Animals: 
48 Wistar Albino Rats (24M + 24F) were selected and divided into 4 groups. Each group 
consist of 12 animals (Male -6, and Female-6). First group treated as a control and other three 
group were treated with test drug (low, mid, high) for  28 days. Animals were allowed 
acclimatization period of 7 days to laboratory conditions prior to the initiation of treatment. Each 
animal was marked with picric acid. The females were nulliparous and non-pregnant. 
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 Justification for Dose Selection: 
         As per OECD guideline three dose levels were selected for the study. They are low dose (X), 
mid dose dose (5X), high dose (10X). X is calculated by multiplying the therapeutic dose (195 
mg) and the body surface area of the rat (0.018). i.e X dose is (5mg), 5X dose is 25mg/animal, 
10X dose is 50mg/animal. 
 
Preparation and Administration of Dose: 
        RASA CHENDHURAM suspended , It was administered to animals at the dose levels of X, 
5X, 10X. The test substance suspensions were freshly prepared every two days once for 28 days. 
The control animals were administered vehicle only. The drug was administered orally by using 
oral gavage once daily for 28 consecutive days. 
 
Observations: 
Experimental animals were kept under observation throughout the course of study for the 
following: 
 
Body Weight: 
 Weight of each rat was recorded on day 0, at weekly intervals throughout the course of study.  
Food and water Consumption: 
  Food and water consumed per animal was calculated for control and the treated dose 
groups.  
Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity and duration 
of these symptoms, if any, were recorded. 
Mortality: 
All animals were observed twice daily for mortality during entire course of      study. 
Necropsy: 
All the animals were sacrificed by excessive anaesthesia on day 29. Necropsy of all animals 
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was carried out. 
Laboratory Investigations: 
Following laboratory investigations were carried out on day 29 in animals fasted over-
night. Blood samples were collected from orbital sinus using sodium heparin (200IU/ml) for Bio 
chemistry and potassium EDTA (1.5 mg/ml) for Hematology as anticoagulant. Blood samples 
were centrifuged at 3000 r.p.m. for 10 minutes. 
Haematological Investigations: 
               Haematological parameters were determined using Haematology analyzer.  
Biochemical Investigations:  
              Biochemical parameters were determined using auto-analyzer. 
Histopathology:  
              Control and highest dose group animals will be initially subjected to histopathological 
investigations. If any abnormality found in the highest dose group than the low, then the mid dose 
group will also be examined. Organs will be collected from all animals and preserved in 10% 
buffered neutral formalin for 24 h and washed in running water for 24 h.  The organ sliced 5 or 
6µm sections and were dehydrated in an auto technicon and then cleared in benzene to remove 
absolute alcohol. Embedding was done by passing the cleared samples through three cups 
containing molten paraffin at 50°C and then in a cubical block of paraffin made by the “L” moulds. 
It was followed by microtome and the slides were stained with Haematoxylin-eosin red. 
Statistical analysis:  
Findings such as body weight changes, water and food consumption, hematology and blood 
chemistry were subjected to One-way ANOVA followed by dunnet t test using a computer 
software programme – Graph pad  version 7.All data were summarized in tabular form, (Table-6 
to 12) 
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PHARMACOLOGICAL STUDY 
IMMUNOMODULATOR ACTIVITY-CELL LINE STUDY 
The evaluation of the immunomodulatory activity of Rasa chendhuram was carried out 
in cultured raw cell line in Biogenix Research Center. 
DETERMINATION OF IN VITRO IMMUNOMODULATORY EFFECT OF 
EXTRACTS ON CULTURED RAW CELL LINES 
RAW 264.7 cells will be grown to 60% confluence followed by activation with 1 µL 
lipopolysaccharide (LPS) (1µg/mL). LPS stimulated RAW cells were exposed with different 
concentration (25, 50, 100 µg/mL) of sample and incubated for 24 hours.  After 24 hours of 
incubation the cells were digested and centrifugation was done at 6000 rpm for 10 minutes. 
Supernatant was discarded and cells were then resuspented in 200µl of cell lysis buffer (0.1M 
TrisHCl, 0.25M EDTA, 2M Nacl, 0.5 % Triton x-100).  The samples were then kept at 40C for 
20 minutes. After incubation, the immuno modulatory response was performed by estimating 
nitrite levels in the cell lysate. 
Estimation of Cellular Nitrite Levels  
The level of nitrite level was estimated by the method of Lepoivre et al. (Lepoivre et. 
al. 1990) To 0.5 mL of cell lysate, 0.1 mL of sulphosalicylic acid was added and 
vortexed well for 30 minutes. The samples were then centrifuged at 5,000 rpm for 15 
minutes. The protein-free supernatant was used for the estimation of nitrite levels. To 
200 μL of the supernatant, 30 μL of 10% NaOHwas added, followed by 300 μL of Tris-
HCl buffer and mixed well. To this, 530 μL of Griess reagent was added and incubated 
in the dark for 10–15 minutes, and the absorbance was read at 540 nm against a Griess 
reagent blank. Sodium nitrite solution was used as the standard. The amount of nitrite 
present in the samples was estimated from the standard curves obtained.  
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ANTI INFLAMMATORY ACTIVITY: 
The evaluation of the  anti inflammatory activity of  Rasa chendhuram was carried out 
in carrageenan induced paw edema models in wister albino rats. 
Anti-inflammatory studies using RASA  Chendhuram (RCM) 
For the experiment, the animals were divided into 5 groups with 6 animals in each 
group. 
 Group-I (control) received 3% gum acacia 10 ml/kg p.o.
 Group-II (Carageenan) received 0.1ml of 1% w/v suspension of carrageenan
S.C
 Group-III (standard) received Indomethacin 40 mg/kg p.o.
 Group-1V(Test-1) received RCM20mg/kg p.o.
 Group-V(Test-2) received  RCM 40mg/kg p.o.
All the drugs were administered orally and the volume of medicaments kept constant 
at 10 ml/kg body weight of the animals it was administered orally to rats 1 hrbefore 
subcutaneous injection of carrageenan. After 1 hr 0.1ml of 1% w/v suspension of 
carrageenan was injected into sub-plantar region of the left hind paw to all the groups. 
The paw volume was measured at 1, 2, 3, 4, and 5 hr using Plethysmometer (Model 
7150 UGO Basile, Italy) Edema was expressed as the mean increase in paw volume 
relative to control animals 
CLINICAL STUDY: 
This study was conducted after getting approval from IEC(Institutional Ethical 
Committee, GSMC  Chennai.IEC No:GSMC-CH-ME-4/2015/013. This study was 
also registered in Clinical Trail Registry  of India CTRI,Ref No/2017/04/014067 , this 
was done in post graduate department SirappuMaruthuvam,Government Siddha 
Medical College and Hospital,Arignar Anna Hospital Campus ,Arumbakkam ,Chennai 
-106.under the observation  and guidance of Head of the department. 
In this clinical study totally 40 cases was enrolled out of which 20 cases were treated 
with Internal and External drugs ,20 cases were treated with Internal and External drugs 
&Ottradam  theraphy . 
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STUDY CENTER: 
OPD of Arignar  anna  Government Hospital of Indian Medicine and Homeopathy 
Arumbakkam Chennai-106. 
TRAIL DRUG: 
Internal drug: Rasa  chendhuram 
External drug: Roga sanjeevi thylam 
External theraphy: Ottradam 
Study period: 48 days 
Sample Size: 40 cases 
20 cases treated with Internal and External drugs  
20 cases treated with Internal and External drugs & Ottradam theraphy 
SUBJECT SELECTION: 
There is considerable number of patients reporting of Room no. 4, PG Sirappu 
Maruthuvaum OPD, Arignaranna govt. hospital, GSMC, with the symptom of inclusion 
criteria will be subjected to screening test and documented using screening proforma.40 
patients who fulfilled  the inclusion criteria were included for the study . 
Patients criteria, clinical assessment, siddha assessment laboratory investigations, 
diagnosis and treatment aspect. In patients after the degree of palliation is achieved they 
were advised to visit OPD for further follow up selection were strictly subjected to 
protocol comprising selection . 
INCLUSION CRITERIA: 
 Age: 18-60 Years
 Sex: Both female & male (Female dominant disease)
 Anti CCP  +ve
 RA factor +ve/ -ve
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 Morning stiffness
 Low grade fever
 Pain and swelling in distal interphalangeal joints .
 Arthritis of  more than 3 joints
 Spindle shape swelling
EXCLUSION CRITERIA: 
KNOWN CASES OF 
 Rheumatic fever
 Psoriatic arthropathica
 Gouty arthritis
 Systemic lupus erythematus
 Progressive systemic sclerosis (PSS)
 History of long term intake of steroids
 Any other serious illness
 Carries spine
 HIV
 Pregnant women and lactating mother
 Tumour
 Osteomyelitis
 Ankylosing spondylitis
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WITHDRAWAL CRITERIA: 
Intolerance  to the drug and development of any serious adverse effect during drug trial. 
Patient turned unwilling to continue in the course of Clinical trial any other systemic 
illness. 
ADR REPORTING: 
If ADR is reported patients will be referred to SCRI (Peripheral Pharmacovigilance 
centre) 
MODERN INVESTIGATION: 
Blood: 
 Hb,
 TC,
 DC,
 ESR,
 BloodSugar, (F)(PP).
Renal Function Tests: 
 Urea,
 Creatinine.
Liver Function Tests: 
 Serum total bilirubin,
 Direct bilirubin,
 Indirectbilirubin,
 Alkaline phosphatase,
 SGOT,
 SGPT.
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Urine : 
 Albumin,
 Sugar,
 Deposits.
X-Ray : 
 Affected joints-AP and Lateral View.
Specific Investigation:  Anti ccp 
STUDY ENROLMENT: 
Patient reporting at the OPD with symptoms of Anti CCP  +ve , RA factor +ve/ -ve , 
Arthritis of  more than 3 joints, Pain and swelling in interphalangeal joints, Spindle 
shape swelling , rheumatoid nodules are chosen for enrolment based on this inclusion 
criteria. The patient who are enrolled are informed about the trial drug, possible 
outcomes and objective of the study in the language and terms understandable to them 
and the informed consent would be obtained in the consent form. 
CONDUCT OF THE STUDY: 
Patients satisfying the inclusion and exclusion criteria will be included in the trial. 
Modern investigations will be carried out before treatment and at the end of the 
treatment. At the end of the study the trial patients are advised to report when there is 
recurrence. 
DATA  COLLECTION FORMS: 
Required information will be collected from each patient by using following forms. 
Form I  : Screening and selection proforma 
Form II   : History taking proforma 
Form III : Clinical assessment proforma 
Form IV : Clinical assessment during and after trial 
Form V : Laboratory investigation proforma 
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Form VI : Informed consent form 
Form VII   : Withdrawal form 
Form VIII : Patients information sheet 
DATA ANALYSIS: 
After enrolling the patients in the study, a separate file for each patient will be 
maintained and all forms will be kept in the file. Whenever the patients visits OPD 
during the study period necessary entries will be made in the assessment forms. The 
data entries and adverse events if any will be monitored by the head of the department. 
OUTCOME OF TREATMENT: 
Primary Outcome: 
 Primary outcome is mainly assessed by reduction in  pain and inflammation of
two joints,
 Reduction of Morning stiffness,
 Pain is assessed by visual pain analogue scale,
 By comparing the any two parameters before and after treatment ESR, Hb, Anti-
CCP, RA factor
Secondary Outcome: 
Secondary outcome is assessed by comparing the safety parameters before and after 
treatment 
ETHICAL ISSUES: 
 Informed consent will be obtained from the patients after explaining about the
clinical trial in regional tongue.
 After the consent of the patient (through consent form) if they are in the
inclusion criteria they will be enrolled in the study.
 Treatment will be provided free of cost.
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 Concomitant medications will be given when required.
 Rescue medications will be given when needed.
 The patients who are excluded (as per exclusion criteria) are given proper
treatment with full care at OPD.
MATERIALS AND METHODS  │2017
114
RESULTS AND OBSERVATIONS │2017 
RESULTS AND OBSERVATIONS 
ORGANOLEPTIC CHARACTER: 
Table of–1- Organoleptic characters of RCM 
S.NO  CHARACTERS  RESULTS 
1. Color Dark Red 
2. Odour Odourless 
3. Taste Tasteless  
4. Appearance Fine Powder  
5. Solubility Sparingly Soluble In Both Water And 
Alcohol  
COLOUR OF THE INGREDIENTS BEFORE AND AFTER PURIFICATION 
Table of-2-color of the ingredients in RCM before and after purification. 
S.NO RAW DRUGS BEFORE
PURIFICATION 
AFTER 
PURIFICATION 
1 Rasam Colourless,dust 
float over it 
Colourless 
2 Gandhagam Yellow solid Yellow granules 
3 Paalthutham     Dirty white   White powder 
TRADITIONAL TESTING METHODS FOR CHENDHURAM 
Table-3- Traditional  testing  method for Rasa chendhuram 
S.NO  TESTS INFERENCE 
1. Floating on water +  
2. Finger furrows test +  
3. Lusterless + 
4. Tasteless + 
5. Colour Dark Red 
INFERENCE: 
Hence it provides the traditional way of testing the trail drug. 
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 PHYSICO- CHEMICAL ANALYSIS OF RASA CHENDHURAM 
  Table –4- Physico chemical analysis of RCM 
Name of the Experiment Value 
Loss on Drying (at 105◦ C) 0 % 
               Total ash 100 % 
               Water Soluble Ash 24.5 % 
               Acid Insoluble Ash 55.11 % 
pH Value (10%) 3.07 % 
INFERENCE: 
LOD of RCM is 0% this shows that less value of moister content 
 Less water soluble ash 24.5% indicator of contamination and adulteration  
 Here the physico -chemical analysis well within the standard range this shows this drug is safe. 
QUALITATIVE ANALYSIS OF HEAVY METALS   
Table no- 5 - Qualitative Analysis of Heavy Metals   
S.NO HEAVY METAL RESULT
1 LEAD ND
2  MERCURY ND 
3 ARSENIC ND
4 CADMIUM ND
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            Acute oral toxicity study of   RASA CHENDHURAM 
Table 6: Dose finding experiment and its behavioral Signs of acute oral Toxicity 
Observation done: 
S NO GroupCONTROL Observatio
n
S NO GroupTEST GROUP Observation
1 Body weight Normal 1 Body weight Normally
increased 
2 Assessments of posture Normal 2 Assessments of posture Normal 
3 Signs of Convulsion 
Limb paralysis 
Normal 3 Signs of Convulsion 
Limb paralysis 
Absence of 
sign (-) 
4 Body tone Normal 4 Body tone Normal 
5 Lacrimation Normal 5 Lacrimation Absence
6 Salivation Normal 6 Salivation Absence
7 Change in skin color No 
significant 
7 Change in skin color No significant 
color change
8 Piloerection Normal 8 Piloerection Normal
9 Defecation Normal 9 Defecation Normal
10 Sensitivity response Normal 10 Sensitivity response Normal 
11 Locomotion Normal 11 Locomotion Normal
12 Muscle gripness Normal 12 Muscle gripness Normal 
13 Rearing Mild 13 Rearing Mild
14 Urination Normal 14 Urination Normal
Behaviour: 
The animals will be observed closely for behavior in the first four hours which  includes abnormal 
gait, aggressiveness, exophthalmos, ptosis, akinesia, catalepsy, convulsion, excitation, head 
twitches, lacrimation, loss of corneal reflex, loss of traction, piloerection  reactivity of touch, 
salivation, scratching, sedation, chewing,  head movements, sniffing, straub, tremor and writhes, 
diarrhea, leathery, sleep and coma. 
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Body Weight: 
Individual weight of animals was determined before the test substance was administered and 
weights will be recorded at day 1, 7, and 14 of the study. Weight changes were calculated and 
recorded. 
 At the end of the test, surviving animals were weighed and humanly killed. 
Food and water Consumption: 
Food and water consumed per animal was calculated for control and the treated dose groups. 
Mortality: 
Animals were observed for mortality throughout the entire period. 
Results: 
All data were summarized in tabular form, (Table-1-4) showing for each test group the 
number of animals used, the number of animals displaying signs of toxicity, the number of animals 
found dead during the test ,description of toxic symptoms,, weight changes, food and water intake 
No of animals in each group:3 
Table 7 (Observational study Results) 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
1. Control + - - + - + - - - - - - - - - - - - - - 
2. 
5mg 
+ - - + - + - - - - - - - - - - - - - - 
1..Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. 
Decreased Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle 
relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhea 18. Writhing  
19. Respiration 20. Mortality.
(+  Present, -  Absent) 
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RESULTS-SUB ACUTE TOXICITY 
Repeated Dose 28- day oral toxic study of  RASA CHENDHURAM 
Table 8: Body weight of wistar albino rats group exposed to RASA CHENDHURAM 
NS- Not Significant, **(p > 0.01),*(p >0.05), n = 10 values are mean ± S.D (One way ANOVA 
followed by Dunnett’s test) 
Table 9: Water intake (ml/day) of Wistar albino rats group exposed to RASA CHENDHURAM 
DOSE DAYS 
1 6 14 21 28
CONTROL 60.2 ± 1.21 60.6±6.12 62.2±4.10 62±4.12 64.6±1.32 
LOW DOSE 62.1±1.10 62.6±2.42 62.9±1.72 63.2±6.86 64.4±1.54 
MID DOSE 58.1±1.26 58.3±3.21 59.1±6.41 59.4±1.72 59.4±1.82 
HIGH DOSE 54.1±1.41 54.2±1.42 54.4±1.44 54.6±1.52 55.8±2.82 
P value (p)* NS NS NS NS NS
N.S- Not Significant, **(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
DOSE DAYS 
1 7 14 21 28
CONTROL 290.2±24.22 291.4 ± 14.24 
291.5 ± 
25.40 
292.5± 35.46 
292.4 ± 
45.15 
LOW DOSE 265.2 ± 46.14 265.4 ± 27.20 267.6± 66.74 268 ± 62.18 268.8± 54.34 
MID DOSE 270.4± 04.24 270.3 ± 46.54 271.2± 68.16 271.4 ± 54.26 
272.4 ± 
64.70 
HIGH DOSE 250.6± 64.94 250.6 ± 50.53 
251.4 ± 
52.44 
251 ± 24.68 252 ± 74.60 
P value (p)* NS NS NS NS NS
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Table 10:Food intake (gm/day) of Wistar albino rats group exposed to RASA 
CHENDHURAM 
DOSE DAYS 
2 7 23 22 28
CONTROL 36±4.12 36.2±3.12 37.3±2.84 37.2±1.41 38±2.43 
LOW DOSE 38.2±1.41 38.3±1.13 38.1±1.21 39.5±1.23 39.5±1.26 
MID DOSE 35.1±3.32 35.2±3.04 35.2±2.42 36.2±2.61 37.2±1.42 
HIGH DOSE 37.1±1.32 37.1±1.41 37.6±2.62 38.2±1.10 39.6±3.42 
P value (p)* NS NS NS NS NS
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test 
Table 11: Haematological parameters of Wistar albino rats group exposed to RASA 
CHENDHURAM 
Category Control Low dose Mid dose High dose P value 
(p)* 
Haemoglobin(g/dl) 15.8±0.68 15.60±0.84 15.8±0.26 15.92±0.65 N.S 
Total WBC (×103   l) 8.71±0.32 8.75±0.26 8.68±0.27 8.60±1.22 N.S 
Neutrophils (%) 29.22±0.01 30.02±0.10 31.11±1.12 32.02±1.02 N.S 
lymphocyte (%) 58.12±1.32 58.12±1.12 58.10±2.33 58.20±2.62 N.S 
Monocyte (%) .06±0.02 .06±0.04 .06±0.01 .06±0.06 N.S 
Eosinophil (%) 0.2±0.04 0.2±0.02 0.2±0.01 0.2±0.06 N.S 
Platelets cells103/µl 543.14±3.43 543.41±4.12 544.13±4.0 545.12±2.54 N.S 
Total RBC 106/µl 7.68±0.12 7.76±0.43 7.69±0.48 7.75±0.26 N.S 
PCV% 49.42±0.2 49.42±1.12 49±1.22 49.60±2.21 N.S 
MCHC g/dL 31.8±1.32 31.24±1.20 32.18±1.10 32.33±1.12 N.S 
MCV fL(µm3) 57.3±3.20 57.2±1.20 57.9±1.24 57.8±1.22 N.S 
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N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One way ANOVA 
followed by Dunnett’s test. 
Table 12 :Biochemical Parameters ofofWistar albino rats group exposed to RASA 
CHENDHURAM 
BIOCHEMICAL 
PARAMETERS 
CONTROL 
LOW 
DOSE 
MID 
DOSE 
HIGH 
DOSE 
P 
Value 
(p)* 
GLUCOSE (R) (mg/dl) 105.14±8.2 105.16±4.10 
106.02±11.
10 
106.12±6.2 N.S 
T.CHOLESTEROL(mg/
dl) 
108.16±1.42 108.25±1.20 
109.62±1.1
8 
109.24±1.63 N.S 
TRIGLY(mg/dl) 64.16±1.42 64.12±1.22 66.16±1.22 66.16±1.22* N.S 
LDL 69.6±2.13 69.12±2.34 69±1.32 
69.24±12.12 
NS 
VLDL 13.4±1.32 13.42±4.24 13.24±2.84 13.54±14.16 NS 
HDL 22.16±6.12 22.42±2.20 23.18±2.26 24.18±22.12 NS 
Ratio 1(T.CHO/HDL) 4.61±1.12 4.62±1.24 4.64±1.14 4.64±2.30 NS 
Ratio 2(LDL/HDL) 2.40±1.14 2.41±1.12 2.41±2.20 2.46±10.02 NS 
Albumin(g/dL) 
4.43±0.16 4.53±0.32 4.44±10.32 
4.42±10.48 
NS 
NS- Not Significant,**(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
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Table 13: Renal function test of ofWistar albino rats group exposed to RASA 
CHENDHURAM 
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
UREA (mg/dl) 21.30±0.99 21.20±0.36 21.16±1.18 21.48±1.21 N.S 
CREATININE(mg/d
l) 
0.42±0.02 0.41±0.04 0.42±0.06 0.44±0.08 N.S 
BUN(mg/dL) 14.1±0.11 14.10±0.60 14±0.32 14.46±1.12 NS 
URIC ACID(mg/dl) 5.00±0.34 5.06±0.21 5.7±0.14* 5.62±0.26 N.S 
 
NS- Not Significant, **(p > 0.01), * (p >0.05) , n = 10 values are mean ± S.D (One way ANOVA  
followed by Dunnett’s test) 
 
Table 14: Liver Function Test of ofWistar albino rats group exposed to RASA 
CHENDHURAM 
 
PARAMETERS CONTROL
LOW 
DOSE 
MID DOSE HIGH DOSE 
P Value 
(p)*  
T 
BILIRUBIN(mg/dl). 
0.03±0.03 0.03±0.02 0.04±0.02 0.04±0.04 N.S 
SGOT/AST(U/L) 139.15±1.33 139.34±0.32 140.01±1.62 140.75±1.02 N.S 
SGPT/ALT(U/L) 72.12±1.18 72.22±1.34 72.14±1.28 72.46±0.61 N.S 
ALP(U/L) 129.22±3.16 129±12.14 130±14.04* 130.23±11.15* N.S 
T.PROTEIN(g/dL) 8.12±0.34 8.18±0.12 8.16±0.14 8.54±0.49 N.S 
 
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One way ANOVA 
followed by Dunnett’s test) 
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PHARMACOLOGICAL  STUDY OF RCM: 
SAMPLE : RASA CHENDHURAM(sikicharathnaDheepam) 
                       Table-15 immunomodulator activity in RCM 
 
 
 
 
 
 
 
Chart I –immunomodulatory result of RCM 
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Sample  Concentration 
(µg/ml) 
OD at 540nm Concentration (µg) 
Control 0.1924 952.38 
25 0.1267 627.165 
50 0.0882 436.59 
100 0.0789 390.555 
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Standard – nitrite level  
Table-- 16 standard nitrate level for immunomodulatory activity 
Concentration (µg) OD (540 nm) 
100 0.021 
200 0.42 
300 0.06 
400 0.08 
500 0.17 
 
INFERENCE:   
While the concentration level is decreased, nitrate level increased.  Hence 25µg/ml of RCM  has 
rich level of nitrate and thus proven to be an Immumomodulator.    
Anti-inflammatory studies using RASA  Chendhuram (RCM)  
For the experiment, the animals were divided into 5 groups with 6 animals in each group. 
 Group-I (control) received 3% gum acacia 10 ml/kg p.o. 
 Group-II (Carageenan) received 0.1ml of 1% w/v suspension of carrageenan S.C 
 Group-III (standard) received Indomethacin 40 mg/kg p.o. 
 Group-1V(Test-1) received RCM20mg/kg p.o. 
 Group-V(Test-2) received  RCM 40mg/kg p.o. 
All the drugs were administered orally and the volume of medicaments kept constant at 10 ml/kg 
body weight of the animals it was administered orally to rats 1 hrbefore subcutaneous injection of 
carrageenan. After 1 hr 0.1ml of 1% w/v suspension of carrageenan was injected into sub-plantar 
region of the left hind paw to all the groups. The paw volume was measured at 1, 2, 3, 4, and 5 hr 
using Plethysmometer (Model 7150 UGO Basile, Italy) Edema was expressed as the mean increase 
in paw volume relative to control animals. 
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PAW EDEMA VOLUME-Table 17 Anti inflammatory in RCM 
Group Dose Initial paw 
volume 
Change in paw edema mm at different time intervals 
  0hr 1 hr 2hr 3hr 4hr 5hr 
I Control 1.20 ± 0.14 1.20±0.14 1.20±0.14 1.20±0.14 1.20±.14 1.20±0.14
II Carrageenan 1.21± 0.17 
1.91 ± 0.21 2.27 ± 0.02 2.37 ± 0.14 2.48 ± 0.18 
2.62 ± 
0.17 
III Indomethacin 1.01± 0.06 
2.10 ± 0.26 1.56 ± 0.15 
1.47 ± 0.05 
 
1.34 ± 0.18 
1.15 ± 
0.16 
 
IV Low dose 1.34 ± 0.13 1.64 ± 0.32 1.74 ± 0.36 1.62 ± 0.64 
 
1.54 ± 0.22 1.49 ± 
0.32 
V High dose  1.32 ±0.44 1.92 ± 0.42 1.86 ± 0.54 
 
1.66 ± 0.64 1.60 ± 0.28 
 
1.40 ± 
0.12 
The paw volume up to the tribiotural articulation was measured at 0, 1, 2, 3, 4, 5 hrs 
Group Initial paw 
volume 
5 hr in mm Difference in paw 
volume 
Percentage 
protection  
I 1.20 ± 0.14 1.20±0.14 0.00 100 
II 1.21± 0.17 2.62 ± 0.17 1.41 15.59 
III 1.01± 0.06 1.15 ± 0.16 
 
0.24 86.67 
IV 1.34 ± 0.13 1.49 ± 0.32 0.15 32.42 
V 1.32 ±0.44 1.40 ± 0.12 0.08 64.54 
 
Percentage protection is calculated by the formulae:  (T2---T1/T2)x 100 
T 1----normal control 
T2----drug treated test 
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 CHART -2 Anti inflammatory results of RCM 
 
 
SELECTION OF CASE : 
 Table- 18 Selection of cases 
 
S NO SELECTION OF CASES NO OF PATIENTS PERCENTAGE % 
1 INTERNAL AND EXTERNAL 20 50% 
2 INTERNAL AND EXTERNAL & 
OTTRADAM THERAPHY 
20 50% 
                                                 Chart –3Selection of case 
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INFERENCE: 
 
Among 40 cases 20 cases (50%) were treated with internal and externaland 20 
cases (50%) were treated with both internal and external and ottradamtheraphy. 
 
.GENDER DISTRIBUTION:  
                                         Table-19 Gender distribution 
 
S.NO GENDER DISTRIBUTION NO.OF PATIENTS PERCENTAGE 
% 
1. MALE  2 5% 
2. FEMALE  38 95% 
 
                                        Chart –4 -Gender distribution 
€  
 
INFERENCE: 
 
Among  40 cases 2cases(5%)were male and 38 cases (95%) were female. 
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AGE DISRTIBUTION: 
 
Table – 20 Age distribution 
 
S.NO  AGE 
DISTRIBUTION  
NO OF CASES  PERCENTAGE%  
1. 18 – 20 0 0% 
2. 21 – 30 5 12.5% 
3. 31 – 40 7 17.5% 
4. 41 – 50 19 47.5% 
5. 51 – 60 9 22.5% 
 
                                         Chart -5 Age distribution 
 
 
 
 
 
 
 
 
INFERENCE: 
 
 
   Among 40 cases high age incidence is between 41-50(47.5%)and 51-60(22.5%) 
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FAMILY HISTORY: 
Table –21- Family History 
S.NO  FAMILY HISTORY NO OF CASES PERCENTAGE % 
1. PRESENT 3 8% 
2. ABSENT 37 92% 
Chart-6 -Family history 
INFERENCE: 
  Among 40 cases only 3 cases(8%)had positive family history of Rheumatoid arthritis 
8%
92%
FAMILY HISTORY
PRESENT ABSENT
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OCCUPATIONAL STATUS: 
Table- 22 -Occupational status 
S.NO  OCCUPATIONAL STATUS NO OF CASES PERCENTAGE% 
1. ENGINEER 1 2.5%
2. TEACHER 1 2.5%
3. DRIVER 0 0%
4. EMPLOYEE 4 10%
5. TAILOR 3 7.5%
6. BUSINESS 2 5%
7. LABOR 5 12.5%
8. HOME MAKER 24 60%
Chart –7 Occupational status 
INFERENCE: 
Among 40 cases 24 cases (60%)are home maker and 5cases(12.5%)are labor 
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SOCIO – ECONOMIC STATUS: 
Table –23- Socio-Economic status 
S.NO  SOCIO – ECNOMIC 
STATUS 
NO OF CASES PERCENTAGE% 
1. POOR 23 57.5%
2. MODERATE 12 30%
3. HIGH 5 12.5%
Chart –8 Socia-Economic status 
INFERENCE: 
Among 40 cases 23cases(57.5%)were poor,12 cases (30%)were from middle class and 5 cases 
(12.5%)were from high class 
57%
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DIET: 
Table-24- Diet Habit 
S.NO DIET NO OF PATIENTS PERCENTAGE % 
1. VEGETARIAN 7 17.5% 
2. NON-VEGETARIAN 33 82.5% 
Chart –9-Diet habit 
INFERENCE: 
Among 40 cases 33(82.5%)cases were non-vegetarian and only 7  (17.5%) cases were vegetarian 
17%
83%
DIET
VEGETARIAN NON-VEGETARIAN
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DURATION OF ILLNESS: 
Table –25- Duration of illness 
S.NO  DURATION OF ILLNESS NO OF CASES  PERCENTAGE 
% 
1. UP TO 6 MONTHS 5 12.5% 
2. 6 MONTH – 1 YEAR 7 20% 
3. 1 – 2 YEARS 14 37.5% 
4. 2 – 3 YEARS 3 7.5% 
5. 3 – 4 YEARS 4 10% 
6. 4 – 6 YEARS 3 17.5% 
7. 6 – 10 YEARS 4 10% 
Chart- 10-Duration of illness 
INFERENCE: 
Among 40 cases 14 cases(37.5%)had 2 years of illness and 7 cases (20%) had 6-1 year of 
illness 4 cases(10%)had chronic illness of 6-10 years. 
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MODE OF ONSET: 
Acute onset :up to 6 months  
Sub-acute :6 months – 3 years  
Chronic :4-10 years  
Table : 26-Mode of Onset 
S.NO MODE OF ONSET NO OF CASES PERCENTAGE % 
1. ACUTE 5 12.5%
2. SUBACUTE 23 57.5%
3. CHRONIC 12 30%
Chart –11-Mode of onset 
INFERENCE: 
Among 40 cases 5cases(12.5%) were suffering from acute illness , 23cases(57.5%) were suffering 
from sub –acute illness and 12 cases(30%)were suffering  from chronic illness. 
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CLINICAL FEATURES: 
Table – 27-Clinical features 
S.NO CLINICAL FEATURE NO OF PATIENTS PERCETNAGE % 
1. PAIN 40 100% 
2. SWELLING 30 75% 
3. MORNING STIFFNESS 40 100% 
4. FEVER 10 25% 
5. POLYARTHRALGIA 25 62.5% 
6. RESTRICTED MOVEMENT 30 75% 
7. ANOREXIA 17 42.5% 
Chart-12-Clinical features 
INFERENCE: 
Among 40 cases all the 40(100%)cases had pain and morning stiffness ,30(75%)cases had  swelling 
and restricted movements,25(62.5%)had  polyarthralgia ,17(42.5%)had anorexia and 10(25%)had 
fever.  
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INVOLVEMENT OF JOINTS: 
 
Table -28-Involvement of joints in RA 
 
S.NO  INVOLVEMENT OF 
JOINTS  
NO OF CASES  PERCENTAGE%  
1. CERVICAL VERTEBRA  7 17.5% 
2. ELBOW JOINT  27 67.5% 
3. WRIST JOINT  36 87.7% 
4. MCP JOINT  40 100% 
5. HIP JOINT  4 10% 
6. KNEE JOINT  27 67.5% 
7. ANKLE JOINT  32 80% 
8. MTP JOINT  37 92.5% 
9. LUMBOSACRAL JOINT  2 5% 
 
Chart – 13-Involvements of joints 
 
 
 
INFERENCE: 
 
Among 40 cases high involvement of joints were MCP and  MTP,40(100%)cases and  
37(92.5%)cases respectively. 
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RESULTS AFTER TREATMENT 
 
IMPROVEMENT IN SUBJECTS TREATED WITH INTERNAL TRIAL DRUG “RASA 
CHENDHURAM “AND EXTERNAL “ROGA SANJEEVI  THYLAM”  IN GROUP I  
SUBJECTS. 
 
IMPROVE MENT OF GROUP I SUBJECTS:  
 
Table-29-Improvement of group I subjects 
 
S 
NO 
CLINICAL FEATURE BEFORE 
TREATMENT 
AFTER 
TREATMENT 
  Subject Percentage Subject Percentage
1. MORNING STIFFNESS>1 hr 20 100% 3 15% 
2. PAIN AND SWELLING OF DIP 
JOINTS  
17 85% 2 10% 
3. ARTHRITIS OF MORE THAN 3 
JOINTS  
19 95% 2 10% 
4. SYMMETRICAL INVOLVEMENT  14 70% 2 10% 
5. RESTRICTION OF MOVEMENTS  9 45% 2 10% 
6. LOW GRADE FEVER  4 20% 1 5% 
 
Chart – 14-Improvement of group I Subjects 
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INFERENCE: 
 
Among 20 cases, 20(100%) cases had morning stiffness, 19(95%) cases had arthritis of more than 
three joints, 17(85%) cases had pain and swelling  ,14(70%) cases had symmetrical joint 
involvement , 9 (45%) cases had restriction of movement, and 4(20%) cases had fever before 
treatment. But after treatment only  3 (15%) cases had morning stiffness, 2(10%) cases had arthritis 
of more than three joints , pain and swelling , symmetrical joint involvement , restriction of 
movement, and 1(5%) cases had fever. 
 
RESULTS: 
 
IMPROVEMENT IN SUBJECTS TREATED WITH INTERNAL DRUG RASA CHENDHURAM 
AND EXTERNAL ROGA SANJEEVI THYLAM&OTTRADAM THERAPHY  IN GROUP II 
SUBJECTS. 
 
IMPROVEMENTS OF GROUP II SUBJECTS: 
 
Table of –30-improvements of group II subjects. 
 
S 
NO  
CLINICAL FEATURE BEFORE 
TREATMENT 
AFTER 
TREATMENT 
  Subject Percentage Subject Percentage
1. MORNING STIFFNESS>1 hr 18 90% 2 10% 
2. PAIN AND SWELLING OF DIP 
JOINTS  
19 95% 1 5% 
3. ARTHRITIS OF MORE THAN 3 
JOINTS  
18 90% 1 5% 
4. SYMMETRICAL INVOLVEMENT  15 75% 2 10% 
5. RESTRICTION OF MOVEMENTS  12 60% 2 10% 
6. LOW GRADE FEVER  5 25% 0 0% 
 
Chart – 15-Improvements of group II Subjects 
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INFERENCE: 
 
Among 20 cases, 18(90%) cases had morning stiffness, 18(90%) cases had arthritis of more than 
three joints, 19(95%) cases had pain and swelling  ,15(75%) cases had symmetrical joint 
involvement , 12 (60%) cases had restriction of movement, and 5(25%) cases had fever before 
treatment. But after treatment only  2 (10%) cases had morning stiffness, symmetrical joint 
involvement , restriction of movement 1(5%) cases had arthritis of more than three joints , pain and 
swelling , and no patients had fever. 
 
REDUCTION OF PAIN:  
 
Severe pain : pain score 7-10 
 
Moderate pain : pain score 4-6  
 
Mild pain : pain score 1-3 
 
No pain : pain score 0 
Reduction of pain 
Table of – 31-Reduction of pain 
 
S.NO REDUCTION OF PAIN BEFORE TREATMENT AFTER TREATMENT 
  Subjects Percentage Subjects Percentage 
1. SEVERE  24 60% 2 5% 
2. MODERATE  11 27.5% 3 7.5% 
3. MILD  5 12.5% 26 65% 
4. NO PAIN  0 0 9 22.5% 
 
Chart – 16-Reduction of pain 
 
 
60%
27.50%
12.50%
0
5% 7.50%
65%
22.50%
0%
10%
20%
30%
40%
50%
60%
70%
SEVERE MODERATE MILD NO PAIN
REDUCTION OF PAIN
BEFORE TREATMENT AFTER TREATMENT
140
RESULTS AND OBSERVATIONS │2017 
INFERENCE: 
 
 
Among 40 cases 24 (60%) cases had severe pain, 11 (27.5%) cases had moderate pain and 5 
(12.5%) cases had mild pain before treatment. But after treatment only 2 (5%)  Patients had severe 
pain, 3 (7.5%)  Patients had moderate pain 26(65%) cases had mild pain and 9 (22.5%) cases had 
no pain. 
 
FUNCTIONAL ABILITY GRADATION: 
Table of -32Functional ability gradation 
 
S.NO  GRADE 
 
 
BEFORE TREATMENT  AFTER TREATMENT 
  Subjects Percentage Subjects Percentage 
1. GRADE I 9 22.5% 28 70% 
2. GRADE II 18 45% 8 20% 
3. GRADE III 12 30% 4 10% 
4. GRADE IV 1 2.5% - - 
 
Chart – 17-Functional ability gradation 
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INFERENCE: 
 
Among  40 cases 9 (22.5%)  cases was fit for all activities, 18(45%) cases had mild restriction in 
movements 12 (30%) cases had moderate restriction in movement and 1 (2.5%) case was bed 
ridden before treatment.   
But after treatment 28 (70%) cases became fit for all activities 8 (20%) cases had mild restriction in 
movement, 4 (10%) had moderate restriction and no one was bed ridden. 
OVER ALL RESULT:  
 
Table of   - 33Improvement of RA 
 
 
S.NO IMPROVEMENT NO OF PATIENTS PERCENTAGE 
1. GOOD 32 80% 
2. MODERATE 4 10% 
3. MILD 4 10% 
4. NO IMPROVEMENT NIL NIL 
 
Chart- 18-Improvement of RA 
 
 
INFERENCE: 
 
Among 40 cases 32(80%)cases were good improvement, 4(10%)cases were moderate 
improvement,4(10%) cases were mild improveme 
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GROUP I  SUBJECTS: BLOOD INVESTIGATION 
SI. 
No 
OP. 
NO AGE/SEX 
Hb (gm) TC (cu.mm) DC ESR Bl sugar 
N L E ½ 
hr 
1/2h
r 
1hr 1hr  R 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 5044 50/F 12.5 12.7 8200 8600 60 62 34 34 6 4 6 4 20 16 89 92 
2 4680 50/F 9.6 10.4 9200 9800 65 61 29 31 4 4 35 27 60 53 79 92 
3 115 58/F 11.1 12.7 8000 8870 65 60 26 29 6 5 29 22 46 21 95 102 
4 3345 28/F 11.1 11.6 4480 6200 53 50 31 34 6 7 40 32 81 72 92 112 
5 102 55/F 11.4 11.4 9100 9700 63 58 23 29 4 3 13 9 30 26 100 113 
6 9385 45/F 10.8 11.2 8900 9600 76 62 21 24 3 3 21 17 65 48 92 96 
7 7506 33/F 13.2 13.6 8700 7800 65 65 29 28 6 7 3 5 10 11 119 120 
8 2413 44/F 12.1 13.5 9100 9100 58 52 28 34 2 3 37 28 61 40 112 138 
9 8022 39/F 11.9 12.3 9000 8900 60 59 36 37 4 4 4 5 10 13 118 105 
10 4453 34/M 14.3 14.5 5100 6700 69 63 26 33 5 4 15 7 25 15 120 117 
11 2056 47/F 12.3 12 8300 8100 56 60 37 34 7 6 5 3 15 12 90 110 
12 1834 51/F 12.4 12.4 7800 8000 54 51 37 32 3 2 12 7 22 14 97 111 
13 3497 50/M 11.4 12.1 8600 8900 55 60 15 46 5 4 15 10 26 22 99 98 
14 4640 27/F 12.2 12.2 7000 6800 68 68 26 27 6 5 17 13 110 80 100 98 
15 8701 27/F 14.3 14.5 5100 6700 69 63 26 33 5 4 15 7 25 15 120 117 
16 2685 48/F 10.4 10.2 9200 9400 54 56 40 41 6 3 22 18 39 30 85 83 
17 8987 48/F 12.8 12.8 11400 11300 64 64 32 32 4 4 4 5 10 13 99 98 
18 4902 43/F 12 12 7600 7600 53 54 43 44 4 2 5 3 15 12 98 99 
19 4782 32/F 12.2 12.2 7000 6800 68 68 26 27 6 5 17 13 110 80 100 98 
20 4457 35/F 10.4 10.2 9200 9400 54 56 40 41 6 3 22 18 39 30 85 83 
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 GROUP II SUBJECTS: BLOOD INVESTIGATION 
SI. 
No 
OP. 
NO AGE/SEX 
Hb (gm) TC (cu.mm) DC ESR Bl sugar 
N L E ½ 
hr 
1/2h
r 
1hr 1hr R 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 1537 46/F 11.0 13.6 7000 9500 55 43 42 48 4 5 10 3 13 10 130 125 
2 5682 60/F 10.2 12.6 8000 10400 76 52 19 24 5 5 21 16 38 29 84 116 
3 1833 42/F 11.2 11.7 7600 10800 66 63 20 25 9 7 22 19 45 38 90 120 
4 5605 40/F 10.6 13.0 8000 8000 67 64 29 31 8 5 27 22 55 48 85 124 
5 6757 41/F 11.2 13.7 9000 9500 51 49 40 43 8 6 12 8 20 17 94 120 
6 6158 30/F 11.6 12.4 9500 12000 76 65 18 20 6 4 24 20 55 50 96 111 
7 5637 50/F 12.1 13.2 6400 8000 64 60 30 34 6 6 10 5 17 12 102 117 
8 5638 46/F 11.2 12.4 7000 6800 64 60 27 29 7 7 13 6 15 9 117 127 
9 4425 42/F 11.8 12.1 7300 7500 54 52 29 31 7 5 8 5 12 9 112 121 
10 5530 46/F 10.4 11.9 6300 7000 55 52 38 40 5 5 15 10 26 22 96 125 
11 9385 47/F 10.6 11.6 8600 8900 55 60 15 46 5 4 44 38 96 84 99 96 
12 2511 54/F 10.2 11.6 8600 9700 72 64 26 32 2 2 40 32 85 76 102 110 
13 2809 39/F 11.8 12.3 6300 7400 60 58 32 36 5 4 13 10 30 22 70 94 
14 1613 56/F 11.8 12.4 7200 7800 55 51 34 37 3 2 12 7 22 11 97 116 
15 1036 46/F 11.0 12.7 8600 9000 58 52 30 34 4 2 25 21 42 36 90 95 
16 6672 45/F 9.4 11.4 8100 8700 55 50 45 47 5 3 2 2 5 4 85 96 
17 8795 47/F 8.2 10.1 9200 9400 54 56 40 41 6 3 22 18 39 30 85 83 
18 7468 44/F 9.7 11.3 6800 7200 68 63 26 27 6 5 70 30 110 80 94 110 
19 5216 28/F 10.4 10.8 9200 9400 54 56 40 41 6 3 22 18 39 30 85 83 
20 9477 50/F 11.6 11.3 8200 8100 57 61 39 37 4 2 42 38 69 50 118 108 
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GROUP I SUBJECTS: URINE ANALYSIS 
S.NO OP.NO AGE/SE
X 
URINE ANALYSIS 
ALBUMIN SUGAR DEPOSIT 
BT AT BT AT BT AT 
pus Epi Pu
s 
Ep
i 
1 5044 50/F NIL NIL NIL NIL 1-3 NIL 1-2 3-4 
2 4680 50/F NIL NIL NIL NIL 1-4 2-3 1-3 2-4 
3 115 58/F NIL NIL NIL NIL 3-6 NIL 2-3 1-2 
4 3345 28/F NIL NIL NIL NIL 1-2 NIL NIL 1-3 
5 102 55/F NIL NIL NIL NIL 1-3 NIL NIL NI
L 
6 9385 45/F NIL NIL NIL NIL 3-5 1-3 2-3 NI
L 
7 7506 33/F NIL NIL NIL NIL 4-5 2-3 NIL NI
L
8 2413 44/F NIL NIL NIL NIL 3-5 3-5 3-4 1-2
9 8022 39/F NIL NIL NIL NIL 1-4 NIL 2-3 NI
L
10 4453 34/M NIL NIL NIL NIL NIL 1-3 2-4 NI
L 
11 2056 47/F NIL NIL NIL NIL NIL NIL 1-4 NI
L
12 1834 51/F NIL NIL NIL NIL 4-6 1-2 NIL NI
L 
13 3497 50/M NIL NIL NIL NIL 3-4 2-4 NIL 3-4 
14 4640 27/F NIL NIL NIL NIL NIL 3-5 NIL 3-5 
15 8701 27/F NIL NIL NIL NIL 1-4 2-3 NIL 2-3 
16 2685 48/F NIL NIL NIL NIL 2-4 NIL 1-3 1-3 
17 8987 48/F NIL NIL NIL NIL NIL 1-4 2-4 NI
L 
18 4902 43/F NIL NIL NIL NIL NIL 2-3 3-4 NI
L
19 4782 32/F NIL NIL NIL NIL 1-2 NIL NIL NI
L 
20 4457 35/F NIL NIL NIL NIL NIL 1-3 NIL NI
L 
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GROUP II SUBJECT: URINE ANALYSIS 
S.NO OP.NO AGE/SEX 
URINE ANALYSIS 
ALBUMIN SUGAR DEPOSIT
BT AT BT AT BT AT 
pus Epi Pus Epi 
1 1537 46/F NIL NIL NIL NIL 1-3 NIL 1-2 3-4 
2 5682 60/F NIL NIL NIL NIL 2-3 NIL 1-3 2-4 
3 1833 42/F NIL NIL NIL NIL 3-6 NIL 2-3 1-2 
4 5605 40/F NIL NIL NIL NIL 1-2 NIL NIL 1-3 
5 6757 41/F NIL NIL NIL NIL 2-3 NIL NIL NIL 
6 6158 30/F NIL NIL NIL NIL 3-5 1-3 NIL NIL 
7 5637 50/F NIL NIL NIL NIL 4-5 2-3 NIL NIL 
8 5638 46/F NIL NIL NIL NIL 3-5 3-5 3-4 NIL 
9 4425 42/F NIL NIL NIL NIL 1-4 NIL 2-3 NIL 
10 5530 46/F NIL NIL NIL NIL NIL NIL 2-4 NIL 
11 9385 47/F NIL NIL NIL NIL NIL NIL 1-4 NIL 
12 2511 54/F NIL NIL NIL NIL 4-6 1-2 NIL NIL 
13 2809 39/F NIL NIL NIL NIL 3-4 2-4 NIL 3-4 
14 1613 56/F NIL NIL NIL NIL NIL 3-5 NIL 3-5 
15 1036 46/F NIL NIL NIL NIL 1-4 2-3 NIL 2-3 
16 6672 45/F NIL NIL NIL NIL 2-4 NIL 1-3 1-3 
17 8795 47/F NIL NIL NIL NIL NIL 1-4 2-4 NIL 
18 7468 44/F NIL NIL NIL NIL NIL 2-3 3-4 NIL 
19 5216 28/F NIL NIL NIL NIL 1-2 NIL NIL NIL 
20 9477 50/F NIL NIL NIL NIL NIL 1-3  NIL NIL 
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GROUP I SUBJECTS: LIVER FUNCTION TEST 
S.NO OP.NO AGE/SEX 
LIVER FUNCTION TEST 
BEFORE  TREATMENT AFTER TREATMENT 
Serum 
Alkaline 
phosphatase
SGOT SGPT Serum 
Alkaline 
phosphatase 
SGOT SGPT 
1 5044 50/F 81 40 39 80 41 39
2 4680 50/F 120 40 42 122 40 42 
3 115 58/F 117 38 43 118 38 43 
4 3345 28/F 128 39 48 124 48 39 
5 102 55/F 91.0 14.7 9.3 90 9.3 14.7 
6 9385 45/F 135 35 46 134 46 35 
7 7506 33/F 118 34 41 115 41 34 
8 2413 44/F 97 29 33 99 33 39
9 8022 39/F 139 42 39 140 39 42 
10 4453 34/M 100.7 39 41 100 41 43 
11 2056 47/F 123 37 40 120 40 41 
12 1834 51/F 82 23 20 90 39 22
13 3497 50/M 40 28 14.9 53 45 17
14 4640 27/F 52 29 33 67 42 32
15 8701 27/F 72 32 42 72 32 42
16 2685 48/F 56 39 40 56 36 42
17 8987 48/F 81 37 47 81 37 45
18 4902 43/F 111 31 31 111 31 39 
19 4782 32/F 132 36 38 132 35 36 
20 4457 35/F 119 38 33 119 37 31 
147
RESULTS AND OBSERVATIONS │2017 
S.NO OP.NO AGE/SEX 
LIVER FUNCTION TEST 
BEFORE  TREATMENT AFTER TREATMENT 
Serum 
Alkaline 
phosphatase 
SGOT SGPT Serum 
Alkaline 
phosphatase 
SGOT SGPT 
1 1537 46/F 160 32 37 141 35 28 
2 5682 60/F 132 38 39 132 38 39 
3 1833 42/F 98 17.2 10.1 94 32 34 
4 5605 40/F 90 30 34 92 35 31
5 6757 41/F 89 33 31 91 37 30
6 6158 30/F 91 35 31.2 94 36 34
7 5637 50/F 56 38 39 58 40 39
8 5638 46/F 78 39.7 45 78 39 43 
9 4425 42/F 72 38 42 71 40 41
10 5530 46/F 81 40 39 80 41 39
11 9385 47/F 120 40 42 122 40 42 
12 2511 54/F 117 38 43 118 38 43 
13 2809 39/F 128 39 48 124 48 39 
14 1613 56/F 91.0 14.7 9.3 90 9.3 14.7 
15 1036 46/F 135 35 46 134 46 35 
16 6672 45/F 118 34 41 115 41 34 
17 8795 47/F 97 29 33 99 33 39
18 7468 44/F 139 42 39 140 39 42 
19 5216 28/F 100.7 39 41 100 41 43 
20 9477 50/F 123 37 40 120 40 41 
GROUP II SUBJECTS: LIVER FUNCTION TEST 
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S.NO OP.NO AGE/SEX 
RENAL FUNCTION TEST 
BEFORE TREATMANT AFTER TREATMANT 
UREA CREATININE UREA CREATININE
1 1537 46/F 22 0.6 21 0.6
2 5682 60/F 24 0.8 22 0.8
3 1833 42/F 28 0.8 28 0.7
4 5605 40/F 22 0.7 22 0.9
5 6757 41/F 24 0.62 23 0.67
6 6158 30/F 24 0.8 24 0.7
7 5637 50/F 28 0.66 26 0.72
8 5638 46/F 26 0.72 22 0.67
9 4425 42/F 34 0.9 29 0.8
10 5530 46/F 20 0.7 18 0.9
11 9385 47/F 27 0.65 24 0.77
12 2511 54/F 26 0.9 25 0.9
13 2809 39/F 18 0.67 16 0.8
14 1613 56/F 28 0.8 28 0.8
15 1036 46/F 18.8 0.8 15 1.2
16 6672 45/F 18.6 0.9 20 0.8
17 8795 47/F 20.7 1.1 21.5 0.9
18 7468 44/F 16 0.7 16 0.67
19 5216 28/F 15 0.9 16 0.92
20 9477 50/F 22 0.81 20.7 0.81
GROUP I SUBJECTS: RFT 
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GROUP II SUBJECTS: RFT 
S.NO OP.NO AGE/SEX 
RENAL FUNCTION TEST 
BEFORE TREATMANT AFTER TREATMANT 
UREA CREATININE UREA CREATININE 
1 5044 50/F 24 0.8 24 0.7
2 4680 50/F 28 0.66 26 0.72
3 115 58/F 26 0.72 22 0.67
4 3345 28/F 34 0.9 29 0.8
5 102 55/F 20 0.7 18 0.9
6 9385 45/F 27 0.65 24 0.77
7 7506 33/F 26 0.9 25 0.9
8 2413 44/F 18 0.67 16 0.8
9 8022 39/F 28 0.8 28 0.8
10 4453 34/M 18.8 0.8 15 1.2
11 2056 47/F 20 0.72 20 0.72
12 1834 51/F 18 0.66 19 0.66
13 3497 50/M 24 1.2 24 1.2
14 4640 27/F 15 0.7 15 0.7
15 8701 27/F 22 0.6 22 1.2
16 2685 48/F 18.6 1.1 18.3 1.5
17 8987 48/F 21 0.74 21 0.8
18 4902 43/F 15.6 0.9 16 0.9
19 4782 32/F 24 0.8 22 0.8
20 4457 35/F 28 0.6 24 0.6
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IMPROVEMENT IN GROUP I SUBJECT: INTERNAL &EXTERNAL MEDICINE 
S.NO OP.NO AGE/SEX 
SPECIFIC  INVESTIGATIONS FOR  RA 
RA FACTOR ANTI CCP 
BT AT BT AT
1 1537 46/F 42.3 36.2 71.0 62.0
2 5682 60/F 19.88 15 7.50 5.60
3 1833 42/F 17.20 12 17.50 13.0
4 5605 40/F 20.1 17 40.10 38.20
5 6757 41/F 19.6 10.5 5.0 3.9
6 6158 30/F 22.4 17.1 14.5 12.9
7 5637 50/F 43.8 34.72 2.50 2.50
8 5638 46/F 21.10 21.10 84.9 73.3
9 4425 42/F 128.1 115.0 4.0 4.0
10 5530 46/F 38 29.0 2.7 2.7
11 9385 47/F 43.3 36.2 4.2 4.2
12 2511 54/F 10.200 10.200 72.2 61.1
13 2809 39/F 15.1 15.1 340.00 329.00
14 1613 56/F 14.0 14.0 16.66 14.1
15 1036 46/F 23.3 23.5 419 407
16 6672 45/F 43.8 31.1 12.0 9.10
17 8795 47/F 43.3 34.2 4.0 4.0
18 7468 44/F 19.2 13.0 5.0 5.0
19 5216 46/F 34.4 26.3 3.0 3.0
20 2685 48/F 95.4 86.3 218.20 202.6
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IMPROVEMENT IN GROUP II SUBJECT: INTERNAL &EXTERNAL MEDICINE AND 
OTTRADAM THERAPHY 
S.NO OP.NO AGE/SEX 
SPECIFIC INVESTIGATIONS FOR RA 
RA FACTOR ANTI CCP 
BT AT BT AT
1 5044 47/F 37.6 28.1 264 211
2 4680 50/F 121.8 111 92.17 86.10
3 115 58/F 52.5 47.5 65.0 52.0
4 3345 28/F 41.1 37.0 5.0 4.1
5 102 55/F 31.2 26.0 4.0 4.0
6 9385 45/F 12.0 12.0 26 19.3
7 7506 33/F 19.0 16.7 16.0 11.0
8 2413 44/F 29.1 21.1 62.0 54.1
9 8022 39/F 16.0 16.3 30.0 26.0
10 4453 34/M 17.7 16.1 5.0 5.0
11 2056 47/F 15.00 15.00 12.3 9.90
12 1834 51/F 23.3 19.7 323 311
13 3497 50/M 41.3 31.0 3.0 3.0
14 4640 27/F 43.6 33.0 9.80 8.10
15 8701 27/F 31.3 27.5 57.5 47.0
16 2685 48/F 95.4 87.5 218.20 190
17 8987 48/F 42.1 36.2 127.25 110.20
18 4902 43/F 67.0 39.79 4.0 4.0
19 4782 32/F 18.9 18.00 5.98 4.1
20 4457 35/F 43.3 28.19 0.63 0.63
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CLINICAL PROGNOSIS 
IMPROVE MENT OF GROUP I SUBJECTS: 
The most popular non parametric statistical tool, namely, McNemar Test analysis has been 
employed to analyses the effectiveness with the help of a hypothesis. 
IMPROVE MENT OF GROUP I SUBJECTS: 
S. 
No 
Clinical features Before Treatment After Treatment 
n% n%
1. Morning stiffness>1 hr 20(100) 3(15)** 
2. Pain and swelling of   dip 
joints
17(85) 2(10)**
3. Arthritis of more than 3 joints 19(95) 2(10)** 
4. Symmetrical involvement 14(70) 2(10)** 
5. Restriction of movements 9(45) 2(10)** 
6. Low grade fever 4(20) 1(5) * 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 20 
Inference:  
Since the p value is significant in all clinical features. So there is significant reducing of 
clinical features among the patients for the treatment of Uthiravadha Suronitham (Rheumatoid 
Arthritis). Hence it is concluded that the treatment was effective and significant. 
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IMPROVEMENT IN GROUP II SUBJECTS: 
The most popular non parametric statistical tool, namely, McNemar Test analysis has been 
employed to analyses the effectiveness with the help of a hypothesis. 
IMPROVE MENT OF GROUP II SUBJECTS: 
S. 
No 
Clinical features Before Treatment After Treatment 
n% n%
1. Morning stiffness>1 hr 18(100) 2(10)** 
2. Pain and swelling of   dip 
joints
19(95) 1(5)**
3. Arthritis of more than 3 joints 18(90) 1(5)** 
4. Symmetrical involvement 15(75) 2(10)** 
5. Restriction of movements 12(60) 2(10)** 
6. Low grade fever 5(25) 0(0) ** 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 20 
Inference:  
Since the p value is significant in all clinical features. So there is significant reducing of 
clinical features among the patients for the treatment of Uthiravadha Suronitham (Rheumatoid 
Arthritis). Hence it is concluded that the treatment was effective and significant. 
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Group I Subjects :Liver Function Test 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
2 SGPT 36.01±10.40 35.88±8.70 0.172 
3 SGOT 34.03±6.72 37.51±7.98 <0.05 
4 Alkaline Phosphatase 99.73±29.32 101.15±26.38 <0.05 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically significant. 
Group II Subjects :Liver Function Test 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
2 SGPT 36.48±10.23 36.53±6.88 0.973 
3 SGOT 34.43±7.22 37.41±7.64 <0.05 
4 Alkaline Phosphatase 105.78±26.14 104.65±23.89 0.294 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically significant. 
GROUP I SUBJECTS :RFT 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 23.10±4.72 21.86±4.19 <0.05 
2 Creatinine 0.77±0.12 0.80±0.13 0.419  
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically significant. 
155
RESULTS AND OBSERVATIONS │2017 
GROUP II SUBJECTS :RFT 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 22.80±4.92 21.41±4.18 <0.05  
2 Creatinine 0.78±0.15 0.86±0.23 <0.05  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically significant. 
GROUP I SUBJECTS:BLOOD INVESTIGATION 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Hb 11.92±1.20 12.22±1.22 <0.05  
2 ESR1hr 40.95±31.10 31.15±23.32 <0.001  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically significant. 
GROUP II SUBJECTS:BLOOD INVESTIGATION 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Hb 10.75±0.96 12.14±0.91 <0.001  
2 ESR1 hr 40.21±29.30 32.47±24.92 <0.001  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically significant. 
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IMPROVEMENT IN GROUP I SUBJECT:INTERNAL &EXTERNAL MEDICINE 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 RA Factor 35.72±28.88 29.87±26.23 <0.001  
2 Anti CCP 67.19±118.90 62.86±114.95 <0.001  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically significant. 
IMPROVEMENT IN GROUP II SUBJECT:INTERNAL &EXTERNAL MEDICINE AND 
OTTRADAM THERAPHY 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 RA Factor 39.07±29.12 32.88±25.86 <0.001  
2 Anti CCP 70.01±96.25 61.04±86.71 <0.05  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically significant. 
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DISCUSSION 
Rheumatoid arthritis is an autoimmune and inflammatory diseases, which means that 
your immune system attacks healthy cells in your body by mistake, causing 
inflammation (Painful, swelling) in the affected parts of the body  in symmetrical 
distribution.  RA mainly attacks the joints, usually multiple joints at once. It commonly 
affect the joints in the hands, wrists and knees . In a joint with RA, the lining of the 
joint becomes inflamed, and the collagen bundles are disturbed, causing damage to joint 
tissue.  
In uthiravatha suronitham is mentioned in siddha literatures begins from the 
correlation  of it signs  and symptoms of the diseases Rheumatoid arthritis.   
The drugs which possesses anti-vatha actions as indicated in siddha literature were 
selected and the siddha trial drugs were by the author in the gunapadam practical 
laborartory of government siddha medical college,after getting proper authentication of 
raw drugs from the medicinal botany department under the supervision of the members 
of the teaching faculty and guided by the Head of the Department of Sirappu 
maruthuvam of the government siddha medical college, Chennai-106 
The internal medicine “RASA CHENDHURAM” was analysed  and Biochemical 
analysis was done.40 Patients were admitted for the trial in  the outpatient ward. Of 
which 20 patients was treated  only with internal and external medicine, and 20 patients 
were treated internal and external  & ottradam theraphy  by the oil “ROGA SANJEEVI 
THYLAM” 
Progress of the patients was followed by and documented regularly. Various criteria 
like distribution of gender, age, occupational status and diet were assessed. Clinical 
manifestations  and assessment of the enhancement in the prognosis of the diseases with 
the trial drugs and with “OTTRADAM” were taken into account for evaluating the 
efficacy of trial drugs. 
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AGE: 
     12.5% of Patients were in the age group of 20-30 
     17.5% of patients were in the age group of 31-40 
     47.5% of patients were in the age group of 41-50 
     22.5%of patients were in the age group of 51-60 
GENDER: 
    5% of patients were in the gender of male 
    95% of patients were in the gender of female. 
OCCUPATIONAL STATUS: 
    60% of patients were in the home makers are affected 
   12.5% of patients were in the labors are affected. 
    Mostly home makers and labors are affected. 
SOCIO-ECONOMIC STATUS: 
         Mostly 57.5% were affected in the socio-economic status of lower income group 
because of the low nutrition and poor hygiene and poor immunity. 
DURATION OF ILLNESS: 
       37.5% of the patients have sub- acute stage of the diseases-(1-2 years) 
CLINICAL FEATURES: 
Mostly 80% of the patients merely have all the above said clinical features of 
the presenting illness. 
CLINICAL PROGRESS WITH INTERNAL AND EXTERNAL MEDICINE: 
Mostly 80% of the patients got relief from the morning stiffness, restricted 
movements. 
About 65-70% of the patients had the progress in their clinical features when 
treated with providing internal and external medicine. 
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CLINICAL PROGRESS WITH INTERNAL AND EXTERNAL MEDICINE 
AND OTTRADAM THERAPHY: 
Mostly 80% of the patients got relief from the morning stiffness, restricted 
movements. 
About 70-75% of the patients had the progress  in their clinical features are 
relieved when treated with providing internal and external medicine and ottradam 
theraphy. 
RESULTS: 
(INTERNAL AND EXTERNAL MEDICINE)-GROUP I SUBJECTS: 
Among 20 cases, 20(100%) cases had morning stiffness, 19(95%) cases had 
arthritis of more than three joints, 17(85%) cases had pain and swelling , 14(70%) cases 
had symmetrical joint involvement, 9 (45%) cases had restriction of movement, and 
4(20%) cases had fever before treatment.  But after treatment only  3 (15%) cases had 
morning stiffness, 2(10%) cases had arthritis of more than three joints, pain and 
swelling, symmetrical joint involvement, restriction of movement, and 1(5%) cases had 
fever. 
RESULTS: 
(INTERNAL AND EXTERNAL MEDICINE AND OTTRADAM THERAPHY)- 
GROUP II SUBJECTS: 
         Among 20 cases, 18(90%) cases had morning stiffness, 18(90%) cases had 
arthritis of more than three joints, 19(95%) cases had pain and swelling, 15(75%) cases 
had symmetrical joint involvement , 12 (60%) cases had restriction of movement, and 
5(25%) cases had fever before treatment. But after treatment only  2 (10%) cases had 
morning stiffness, symmetrical joint involvement , restriction of movement 1(5%) cases 
had arthritis of more than three joints, pain and swelling, and no patients had fever. 
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OVERALL RESULTS: 
Among 40 cases 32(80%)cases were good improvement, 4(10%)cases were 
moderate improvement, 4(10%) cases were mild improvement. 
GRADING OF RESULTS: 
There is  certainly marked improvement noted in the grading of the result before 
and after treatment. 
STATISTICAL REPORT: 
Inference:  
Since the p value is significant in all clinical features. So there is significant 
reducing of clinical features among the patients for the treatment of Uthiravadha 
Suronitham (Rheumatoid Arthritis). Hence it is concluded that the treatment was 
effective and significant. 
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SUMMARY 
Clinical study on safety and efficacy of RASA CHENDHURAM  internally and 
ROGA SANJEEVI THYLAM externally with OTTRADAM theraphy  in 
UTHIRAVADHA SURONIDHAM has been chosen for my dissertation work. 
Various literatures dealing with Rheumatoid arthritis had been collected from siddha 
and modern text book as well as drug review was mentioned in my dissertation . 
Standardization of drug RASA CHENDHURAM through both traditional and modern 
techniques. 
Quantitative and qualitatitive analysis of trial drug Rasa chendhuram was carried out 
,along with heavy metal analysis and physic-chemical  analysis. 
Acute and sub-acute toxicity of trial drug RASA CHENDHURAM was carried out in 
Wister albino rats after obtaining proper permission from institutional animal ethical 
committee. 
Pharmacological activity, in vitro immune-modulatory activity for the trail drug RASA 
CHENDHURAM was using cell line RAW 264.7. 
Anti inflammatory activity for the trial drug RASA CHENDHURAM was carried out 
left hind paw oedema volume. 
The clinical trial was conducted to evaluate the efficacy of the trial drugs RASA 
CHENDHURAM (INT), and ROGA SANJEEVI THYLAM THYLAM (EXT) 
WITH “OTTRADAM THERAPY in Rheumatoid arthritis patients, after getting 
proper approval from institutional ethical committee. 
The sample size was 40 patients, the duration was 24 days. 20 patients were treated 
with internal and external medicine. (group I), 20 patients were treated with internal 
and external & ottradam theraphy (group II). 
The internal drug RASA CHENDHURAM was administered at the dose of 65mg 
twice daily, with honey. 
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In my clinical trial some patients had Anti-CCP negative while before treatment, even 
though their clinical symptoms matched with my inclusion criteria, I also added them 
to my clinical trial. 
All the details about the study and the drugs were informed to the patients in their 
vernacular language and consent forms duly signed by them were obtained from them. 
Separate proforma was maintained for each and every patient. 
The clinical improvement was assed using pain score 
Safety of the trial drug RASA CHENDHURAM was assessed by comparing the safety 
parameters LFT & RFT before and after treatment. 
Finally the statistical analysis was performing to assess the significance of the clinical 
trial. 
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CONCLUSION 
This study was conducted with the siddha medicines “RASA CHENDHURAM” 
(Internal) and ROGA SANJEEVI THYLAM (External).These medicines are 
indicated for vatha diseases in siddha texts. 
Heavy metal analysis of RCM reveal that the drug does not contain any metals like 
lead,cadmium,arsenic,mercury. 
The acute and sub acute toxicity study reveals  that the trial drugs RCM is safe, sub –
acute toxicity studies two doses were administrated orally for 28 days Animals were 
observed for physiological and behavioural changes food and water, intake body 
weight, mortality. All the animals were sacrifices, the changes in organ weight and 
histology were examined no mortality were observed and no treatment related changes 
seen.Hence the siddha trial drugs RCM is  safe in animal models  
While the concentration level is decreased,nitrate level is increased. Hence 25µg/ml of 
Rasa Chendhuram has rich level of nitrate and thus proven to be an 
IMMUNOMODULATOR . 
Anti inflammatory activity using in RCM . The paw volume was measured at 1, 2, 3, 
4 and 5hr using Plethysmometer (Model 7150 UGO Basile, Italy) Edema was expressed 
as the mean increase in paw volume relative to control animals. 
Among the study sample 80%had good improvement, 10% had moderate 
improvement,and 10% had mild improvement.The results of the study reveal the fact 
that these medicines are efficacious in reducing morning stiffness, pain and swelling, 
restricted movement, in uthira vatha suronitham with assessing all the safety parameters 
of blood before and after treatment. 
OTTRADAM theraphy along with siddha trial drugs was very effective as the overall 
improvement was good and to certain extent earlier in the subjects who were given 
ottradam theraphy. Many of these subjects had reduction or relief from morning 
stiffness, pain and restricted movements for about four to five hours manipulating the 
ottradam theraphy. 
The LFT &RFT before and after treatment does not show any significant change in 
rheumatoid cases hence it is safe in human trial. In my clinical trial during the course 
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of the trial there were no adverse effect or unwanted drug reactions in GIT, RS, CVS 
and excretory system. 
Hence the siddha trial drug  “RASA CHENDHURAM” Internal medicine is proved 
to be a  potential Anti-Rheumatoid and “ROGA SANJEEVI THYLAM”  with 
Ottradam  theraphy externally  are effective in reducing morning stiffness, pain and 
swelling of the joints, restricted movements in uthira vatha suronidham. (Rheumatoid 
arthritis) 
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GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
AN OPEN COMPARATIVE CLINICAL STUDY ON “UDHIRAVADHA  
SURONITHAM”(RHEUMATOID ARTHRITIS) WITH THE EVALUATION OF 
SIDDHA  TRIAL DRUG “RASA CHENDURAM” (INT), “ROGA SANJEEVI 
THYLAM”  (EXT)&OTTRADAM. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
FORM l - SCREENING AND SELECTION PROFORMA 
1. OP NO:  ................................................................. 
2. NAME:  ………………………………………….  
3. AGE:      ………       4.GENDER: …………....... 
5. OCCUPATION: ………………………………..     6.INCOME:   ……………… 
7. ADDRESS:    ……………………………………    
…………………………………… 
…………………………………… 
8. CONTACT NO:    ……………………………………              
 INCLUSION CRITERIA: 
 Age: 18-60 Years 
 Sex: Both female & male (Female dominant disease) 
 Anti CCP  +ve 
 RA factor +ve/ -ve 
 Morning stiffness 
 Low grade fever 
 Pain and swelling in distal interphalangealjoints . 
 Arthritis of  more than 3 joints 
 Spindle shape swelling 
EXCLUSION CRITERIA 
.KNOWN CASES OF 
 Rheumatic fever 
 Psoriatic arthropathica 
 Gouty arthritis 
 Systemic lupus erythematus 
 Progressive systemic sclerosis(PSS) 
 History of long term intake of steroids 
 Any other serious illness 
 Carries spine 
 HIV 
 Pregnant women and lactating mother 
 Tumour 
 Osteomyelitis 
 Ankylosing spondylitis 
ADMITTED TO TRIAL: 
                          YES                        NO                 
 
      If yes,             OPD/IPD                    
Date:        
Station: 
Signature of the Guide:    Signature of the Investigator:   
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN COMPARATIVE CLINICAL STUDY ON “UDHIRAVADHA  
SURONITHAM”(RHEUMATOID ARTHRITIS) WITH THE EVALUATION OF 
SIDDHA  TRIAL DRUG “RASA CHENDURAM” (INT), “ROGA SANJEEVI 
THYLAM”  (EXT)&OTTRADAM. 
FORM lI -HISTORY TAKING PROFORMA 
 
1. SERIAL NO OF THE CASE: …….  2.OP/IP NO: ........................................... 
3. NAME: ………………………………… 4. AGE: …….. 5. GENDER: …….. 
5. OCCUPATION: ………………………………  6. INCOME:   ………………….. 
7.COMPLAINTS & DURATION:   
 
 
 
 
                                                                                                                                                         
8. PERSONAL HISTORY: 
PERSONAL HABITS YES NO IF YES, SPECIFY 
DURATION/QUANTITY
Smoking    
Tobacco Chewing    
Alcoholism    
Narcotic drugs    
 
9. HISTORY OF PREVIOUS ILLNESS/PELVIC SURGERY 
 
 
10. DIETARY HABIT:     
             1. Vegetarian              
             2. Non-vegetarian 
11. FAMILY HISTORY: 
               Whether this problem runs in family? 
                                         1. Yes                               2.No         
If yes, mention the relationship of affected person(s) --------------------- 
History of previous investigations if any ------------------------------ 
 
 
Date:          
Station: 
Signature of the Guide:    Signature of the Investigator:   
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN COMPARATIVE CLINICAL STUDY ON “UDHIRAVADHA  
SURONITHAM”(RHEUMATOID ARTHRITIS) WITH THE EVALUATION OF 
SIDDHA  TRIAL DRUG “RASA CHENDURAM” (INT), “ROGA SANJEEVI 
THYLAM”  (EXT)&OTTRADAM. 
 
FORM III – CLINICAL ASSESSMENT PROFORMA: 
 
1. SERIAL NO: …………………   
2. OP / IP NO: ......................................   
3. NAME: ……………………………   4.AGE: ……     5.GENDER: .................            
                
GENERAL EXAMINATION: 
Height (cms)                : ………………………….                   
Weight (kg)    : ………………………….                   
Temperature(°F)     : ………………………….                   
Pulse rate(/min)   : ………………………….                   
Heart rate(/min)   : ………………………….                   
Respiratory rate(/min)  : ………………………….                   
Blood pressure(mm/Hg)       : ………………………….           
    
 
Present           Absent 
 
Pallor  
Jaundice 
Cyanosis 
Lymphadenopathy 
Pedal edema 
Clubbing 
Jugular vein pulsation 
SYSTEMIC EXAMINATION 
CardioVascular System  : ………………………….                   
 
Respiratory system   : ………………………….                   
 
Gastro-intestinal system  : ………………………….                   
 
Central Nervous System  : ………………………….                   
 
Urogenital system   : ………………………….                   
 
Endocrine System   : ………………………….                   
 
SIDDHA SYSTEM OF EXAMINATIONS: 
1. THEGI:  [BODY CONSTITUTION]  
1. Vatha udal 
2. Pitha udal 
3. Kaba udal 
4. Thontha udal        
2. NILAM:  [LAND WHERE PATIENT LIVED MOST] 
   1. Kurinji 
   2. Mullai                
    3. Marutham 
4. Neithal  
     5. Paalai 
3. KAALAM: 
1. Kaar kaalam                               4.Pinpani kaalam      
2. Koothir kaalam                           5. Ilavenil kaalam 
3. Munpani kaalam                           6.Muthuvenil kaalam 
4. GUNAM: 
           1.Sathuvam                2.Raasatham             3.Thaamatham 
5. IMPORIGAL (SENSORY ORGANS): 
                                                                        Normal/Affected 
Mei      -------------------------------------------- 
Vaai       ------------------------------------------- 
Kann   ------------------------------------------- 
Mukku  ------------------------------------------- 
Sevi  ------------------------------------------- 
6. KANMENDHIRIYAM (MOTOR ORGANS): 
Kai   ------------------------------------------- 
Kal    ------------------------------------------- 
Vaai  ------------------------------------------- 
Eruvai   ---------------------------------------- 
Karuvaai   ------------------------------------- 
7. KOSANGAL (SHEATH): 
Annamaya kosam  ---------------------------- 
Pranamaya kosam ---------------------------- 
Manomaya kosam ---------------------------- 
Vignana maya kosam ------------------------ 
Anandamaya kosam ------------------------- 
 
8. UYIR THAATHUKKAL: [THREE HUMORS] (VALI,  AZHAL, IYAM) 
A) VALI 
 Pranan –----------------------- 
Abanan ------------------------ 
Samanan ----------------------- 
Uthanan ------------------------ 
Vyanan -------------------------- 
Naagan -------------------------- 
Koorman ------------------------ 
Kirukaran ----------------------- 
Devathathan -------------------- 
Dhananjayan -------------------- 
B) AZHAL 
Analakam ----------------------- 
Ranjakam ----------------------- 
Sathakam ------------------------ 
Prasakam ------------------------- 
Alosakam -------------------------- 
 
C) IYAM 
Avalambagam ------------------------ 
Kilethagam --------------------------- 
Pothagam ------------------------------ 
Tharpagam ---------------------------- 
Santhigam ------------------------------ 
9. SEVEN UDAL THATHUKKAL: (SEVEN SOMATIC COMPONENTS)  
Saram ----------------------- 
Senneer --------------------- 
Oon -------------------------- 
Koluppu -------------------- 
Enbu ------------------------- 
Moolai ------------------------ 
Sronitham -------------------- 
10. ENVAGAI THERVU: 
I. NAADI: [PULSE PERCEPTION]         
II. SPARISAM: [PALPATION] 
III. NAA: [TONGUE] 
 
IV. NIRAM: [COMPLEXION]   
    1. Vadham         
     2. Pitham 
      3. Kabam  
V.MOZHI: [VOICE] 
            1. High Pitched 
            2. Low Pitched 
                        3. Medium Pitched 
VI.VIZHI: [EYES] 
VII. MALAM: [BOWEL HABITS / STOOLS] 
Niram 
Irugal 
Ilagal 
Others 
 VIII. MOOTHIRAM [URINE EXAMINATION]   
NEERKKURI: 
Niram 
Manam 
Edai 
Nurai 
Enjal 
 
NEIKKURI 
 
Date:      
Station: 
Signature of the Guide:    Signature of the Investigator: 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN COMPARATIVE CLINICAL STUDY ON “UDHIRAVADHA  
SURONITHAM”(RHEUMATOID ARTHRITIS) WITH THE EVALUATION OF 
SIDDHA  TRIAL DRUG “RASA CHENDURAM” (INT), “ROGA SANJEEVI 
THYLAM”  (EXT)&OTTRADAM. 
FORM IV : LABORATORY INVESTIGATIONS PROFORMA 
1. SERIAL NO OF THE CASE: …………………   
2.OP / IP NO: ......................................   
3. NAME: ……………………………   4.AGE: ……     5.GENDER: .................   
A) BLOOD INVESTIGATIONS:                        
BLOOD INVESTIGATIONS BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Hb ( gm/dL)   
ESR (mm) ½ hr.   
  1 hr.   
T.WBC (Cells / Cu.mm)   
Differential Count (%) Polymorphs   
  Lymphocytes   
  Monocytes   
  Eosinophils   
  Basophils   
 
 BLOOD INVESTIGATIONS BEFORE 
TREATMENT 
AFTER 
TREATMENT 
F   
  PP   
 
B) URINE INVESTIGATIONS: 
URINE 
INVESTIGATIONS 
BEFORE TREATMENT AFTER TREATMENT 
Albumin   
          Sugar   
Deposits   
C) RADIOLOGICAL EXAMINATIONS 
X-ray-Affected joints  AP view and lateral view. 
 BEFORE TREATMENT AFTER TREATMENT  
X-ray-
Changes. 
 
  
 
Date:          
Station: 
Signature of the Guide:    Signature of the Investigator:   
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN COMPARATIVE CLINICAL STUDY ON “UDHIRAVADHA  
SURONITHAM”(RHEUMATOID ARTHRITIS) WITH THE EVALUATION OF 
SIDDHA  TRIAL DRUG “RASA CHENDURAM” (INT), “ROGA SANJEEVI 
THYLAM”  (EXT)&OTTRADAM. 
 
FORM V: INFORMED CONSENT FORM 
“I have read the foregoing information, or it has been read to me. I have had 
the opportunity to ask questions about it and any questions I have asked have been 
answered to my satisfaction. 
            I   consent voluntarily to participate in this study and understand that I have 
the   right to withdraw from the study at any time without in any way it affecting my 
further medical care”. 
"I have received a copy of the information sheet/consent form". 
Date: 
Signature of the participant: 
In case of illiterate participant 
  “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm 
that the individual has given consent freely.”                                                   
Date: 
 Signature of a witness                          Left thumb Impression of the Participant     
(Selected by the participant bearing no connection with the survey team)       
Date:    
Station:                                                                                  
Signature of participant: 
Signature of the Guide:    Signature of the Investigator:   
«ÃÍ º¢ò¾ ÁÕòÐÅì ¸øæ¡¢, ¦ºý¨É-106 
«È¢»÷ «ñ½¡ ÁÕòÐÅÁ¨É, ¦ºý¨É 
உதிரவாத சுேராணிதம் (ரச ெசந்தூரம் & உேராக சஞ்சீவி ைதலம் & 
ஒற்றடம்) 
À¡¢¸¡¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ. 
´ôÒ¾ø ÀÊÅõ 
¬öÅ¡ÇÃ¡ø º¡ýÈÇ¢ì¸ôÀð¼Ð 
    ¿¡ý þó¾ ¬ö¨Å ÌÈ¢ò¾ «¨ÉòÐ Å¢ÀÃí¸¨ÇÔõ §¿¡Â¡Ç¢ìÌ ÒÃ¢Ôõ 
Å¨¸Â¢ø ±ÎòÐ¨Ãò§¾ý ±É ¯Ú¾¢ÂÇ¢ì¸¢§Èý. 
§¾¾¢:       ¨¸¦Â¡ôÀõ: 
þ¼õ:       ¦ÀÂ÷     : 
§¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø 
±ýÉ¢¼õ  þó¾ ÁÕòÐÅ ¬öÅ¢ý ¸¡Ã½ò¨¾Ôõ, ÁÕó¾¢ý ¾ý¨Á ÁüÚõ 
ÁÕòÐÅ ÅÆ¢Ó¨È ÀüÈ¢Ôõ, ¦¾¡¼÷óÐ ±ÉÐ ¯¼ø þÂì¸ò¨¾ ¸ñ¸¡½¢ì¸×õ, 
«¾¨É À¡Ð¸¡ì¸×õ ÀÂýÀÎõ ÁÕòÐÅ ¬ö×ìÜ¼ ÀÃ¢§º¡¾¨É¸û ÀüÈ¢   ¾¢Õô¾¢ 
«Ç¢ìÌõ Å¨¸Â¢ø ¬ö× ÁÕòÐÅÃ¡ø Å¢Çì¸¢ì ÜÈôÀð¼Ð. 
¿¡ý þó¾ ÁÕòÐÅ ¬öÅ¢ý §À¡Ð, ¸¡Ã½õ ±Ð×õ ÜÈ¡Áø, ±ô¦À¡ØÐ 
§ÅñÎÁ¡É¡Öõ þó¾ ¬öÅ¢Ä¢ÕóÐ   ±ý¨É Å¢ÎÅ¢òÐ ¦¸¡ûÙõ ¯Ã¢¨Á¨Â 
¦¾Ã¢ó¾¢Õì¸¢ý§Èý. ¿¡ý ±ýÛ¨¼Â Í¾ó¾¢ÃÁ¡¸ §¾÷× ¦ºöÔõ ¯Ã¢¨Á¨Âì 
¦¸¡ñÎ உதிரவாத சுேராணிதம் §¿¡öì¸¡É ரச ெசந்தூரம் ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò 
¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢üÌ ±ý¨É ¯ðÀÎò¾ ´ôÒ¾ø «Ç¢ì¸¢§Èý. 
§¾¾¢ :        ¨¸¦Â¡ôÀõ : 
þ¼õ :        ¦ÀÂ÷          : 
 
§¾¾¢  :        º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ : 
þ¼õ  :       ¦ÀÂ÷       :                        
¯È×Ó¨È : 
 
Ð¨Èò¾¨ÄÅ÷ ¨¸¦Â¡ôÀõ :    ¬Ã¡öîº¢Â¡Ç÷ ¨¸¦Â¡ôÀõ:         
GOVERNMENT SIDDHA MEDICAL COLLEGE, CHENNAI 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN COMPARATIVE CLINICAL STUDY ON “UDHIRAVADHA  
SURONITHAM”(RHEUMATOID ARTHRITIS) WITH THE EVALUATION OF 
SIDDHA  TRIAL DRUG “RASA CHENDURAM” (INT), “ROGA SANJEEVI 
THYLAM”  (EXT)&OTTRADAM. 
 
FORM VI - WITHDRAWAL FORM 
SI NO:                 
OP / IP NO:                                               
NAME: 
AGE / GENDER:                
DATE OF TRIAL COMMENCEMENT: 
DATE OF WITHDRAWAL FROM TRIAL: 
REASONS FOR WITHDRAWAL: 
• Long absence at reporting :                                    Yes/ No 
• Irregular treatment:                                                Yes/ No 
• Shift of locality :                                                    Yes/No 
• Increase in severity of symptoms:                         Yes/No 
• Development of severe adverse drug reactions:    Yes/No 
 
 
Date:          
Station: 
Signature of the Guide:    Signature of the Investigator:   
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN COMPARATIVE CLINICAL STUDY ON “UDHIRAVADHA  
SURONITHAM”(RHEUMATOID ARTHRITIS) WITH THE EVALUATION OF 
SIDDHA  TRIAL DRUG “RASA CHENDURAM” (INT), “ROGA SANJEEVI 
THYLAM”  (EXT)&OTTRADAM. 
FORM VII – PATIENT INFORMATION SHEET 
Name of Co- Investigator: C.ARUNA 
Name of the college:  Govt. Siddha Medical College 
                                      Arumbakkam 
                                      Chennai-106. 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
       I, C.Aruna studying M.D (Siddha) at Govt.Siddha Medical College, Chennai,  
is doing a clinical trial on “UTHIRA VADHA SURONITHAM(RHEUMATOID 
ARTHRITIS) It is becoming a most common disease, occurring throughout the world. 
In this regard, I am in need to ask you few questions. I will maintain confidentiality of 
your comments and data obtained. There will be no risk of disclosing your identity and 
no physical, psychological or professional risk is involved by taking part in this study. 
Taking part in this study is voluntary. No compensation will be paid to you for taking  
part in this study. 
           You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, 
taking part in the study may be of benefit to the community, as it may help us to 
understand the problem of defaulters and potential solutions. 
              
If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal medicine 
Rasa chenduram 122-244mg with honey. 
  The information I am collecting in this study will remain between you and the 
Co- investigator (myself). I will ask you few questions through a questionnaire. I will 
not write your name on this form. I will use a code instead. 
The questionnaire will take approximately 20 minutes of your time. 
If you wish to find out more about this study before taking part, you can ask me 
all the questions you want or contact C.Aruna, PG Scholar cum Co- investigator of this 
study, attached to Govt. Siddha Medical College, Chennai-106. You can also contact 
the Member-secretary of Ethics committee, Govt.Siddha Medical College, Chennai. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 «ÃÍ º¢ò¾ ÁÕòÐÅì ¸øæ¡¢, ¦ºý¨É-106 
«È¢»÷ «ñ½¡ ÁÕòÐÅÁ¨É, ¦ºý¨É 
உதிரவாத சுேராணிதம் (ரச ெசந்தூரம் & உேராக சஞ்சீவி ைதலம் & 
ஒற்றடம்) 
À¡¢¸¡¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ 
 
¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷: ÁÕòÐÅ÷. ச. அருணா 
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷ : «ÃÍ º¢ò¾ ÁÕòÐÅì ¸øæ¡¢ 
«ÕõÀ¡ì¸õ, 
   ¦ºý¨É-106 
 
«ÃÍ º¢ò¾ ÁÕòÐÅì ¸øæ¡¢Â¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕõ ¿¡ý 
ÁÕòÐÅ÷. ச.அருணா , உதிரவாத சுேராணிதம் ±ýÛõ §¿¡Â¢ø ÁÕòÐÅ 
¬Ã¡öîº¢Â¢ø ®ÎÀðÎû§Çý.    
  
 
þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Çì §¸ð¸×õ, §¾¨ÅÂ¡É ¬öÅ¸ô 
ÀÃ¢§º¡¾¨ÉìÌ ¾í¸¨Ç ¯ðÀÎò¾×õ ¯û§Çý. 
          þó¾ ¬Ã¡öîº¢ìÌ ¾¡í¸û Å¢ÕôÀò¾¢ý §ÀÃ¢ø ¯ ðÀÎõ Àðºò¾¢ø ¯ûÁÕó¾¡¸  
“ரச ெசந்தூரம் 122-244 மி¸¢ §¾É¢ø 2 §Å¨Ç(¸¡¨Ä, Á¡¨Ä) ¯½×ìÌ À¢ý 48 
¿¡ð¸û ¯ð¦¸¡ûÇ §ÅñÎõ..  ெவளி மருந்தாக உேராக சஞ்சீவி ைதலம்  48 நாட்களுக்கு 
ேநாய் உள்ள இடங்களில் ெவளிேய தடவி ஒற்றடம் ெசய்ய ேவண்டும்.¦ÅÇ¢ §¿¡Â¡Ç÷¸û 7 
¿¡ð¸ÙìÌ ´ÕÓ¨È ÁÕòÐÅÁ¨ÉìÌ ÅÃ §ÅñÎõ.  
 
þó¾ ¬Ã¡öîº¢Â¢ø ¾í¸¨Ç «ÛÁ¾¢ò¾ À¢ÈÌ ¯í¸ÙìÌ Å¢ÕôÀõ 
þø¨Ä¦ÂÉ¢ø ±ô§À¡Ð §ÅñÎÁ¡É¡Öõ ¬Ã¡öîº¢Â¢ø þÕóÐ Å¢ல¸¢ì ¦¸¡ûÇ 
¯Ã¢¨Á ¯ûÇÐ.  
           þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ §¿¡Â¢ý ¾ý¨Á ÀüÈ¢Ôõ ÁüÈ Å¢ÀÃí¸ÙìÌõ 
¬Ã¡öîº¢Â¡ÇÃ¡É ÁÕòÐÅ÷: ச.அருணா, (Àð¼ §Áü ÀÊôÀ¡Ç÷  சிறப்பு ÁÕòÐÅ 
Ð¨È) «Å÷¸¨Ç ±ó¾ §¿Ãò¾¢Öõ ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ ¨¸ô§Àº¢ ±ñ: 9789974091 
 §ÁÖõ þó¾ ¬Ã¡öîº¢ìÌ ¾ì¸ «ÛÁ¾¢î º¡ýÚ (IEC) ¦ÀÈôÀðÎûÇÐ. 
 §ÁÖõ ¯½× Ó¨ÈÂ¢ø ÁÕòÐÅÃ¡ø ÜÈôÀÎõ Àò¾¢Âõ ¸¡ìÌÁ¡Ú 
«È¢×Úò¾ ÀÎ¸¢ÈÐ.  
 þÐ ºõÀó¾Á¡É ¾í¸ÇÐ «¨ÉòÐ Å¢ÅÃí¸Ùõ Ã¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ ±É 
¯Ú¾¢«Ç¢ì¸¢§Èý.  
 þ¾¢ø ÀÂ½ôÀÊ Ó¾Ä¢Â ±ó¾ ¯¾Å¢ò ¦¾¡¨¸Ôõ ÅÆí¸ô À¼ Á¡ð¼¡Ð.  
 þó¾ ¬Ã¡öîº¢Â¢ý §À¡Ð ¯¼ÖìÌ §ÅÚ À¡¾¢ôÒ ²üÀÎõ Àðºò¾¢ø «È¢»÷ 
«ñ½¡ ÁÕòÐÅÁ¨ÉÂ¢ø, ¾ì¸ º¢¸¢î¨º «Ç¢ì¸ôÀÎõ. 
இந்த மருந்து சிறப்பாக உதிரவாத சுேராணிதம் ேநாய்க்காக அங்கீகrக்கப்பட்ட சித்த 
மருத்துவ நூலில் கூறப்பட்டுள்ளது. ஏற்கனேவ உபேயாகத்தில் உள்ள இது ேபான்ற மருந்து 
இதுவைர ேநாயாளிகளிடம் எந்தவித பக்கவிைளவுகைள ஏற்படுத்தவில்ைல. 









